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ABSTRACT
Dietary bioactive compounds benefit health while some might induce pathological processes.
Parkinson’s disease (PD) is the second most common neurodegenerative disease. Braak and Hawkes
hypothesized that the gastrointestinal tract may be a potential site of neuronal invasion by an “unknown
pathogen” leading to some Parkinsonism. Neurotoxin botulinum or ricin can trans-synaptically transport
in nervous system. Our hypothesis 1: dietary plant lectins might be responsible for the “unknown
pathogen” causing PD. Pomegranate juice (PJ) have antioxidant and anti-obesity effects. Our hypothesis
2: PJ increases lifespan in C. elegans and reduces fat storage.
Study 1: Post-feeding rhodamine or TRITC tagged dietary lectins was tracked from gut to
dopaminergic (DAergic) neurons in C. elegans BZ555 (egIs1[Pdat-1::GFP]) that has Green Fluorescent
Protein (GFP) gene fused to a dopamine transport protein gene labeling DAergic neurons. Although this
observation was tested with specific inhibiting sugars (SIS), supplemented with Escherichia coli, the high
concentrations of monosaccharides necessary may have their own side effects. Results showed that
Amaranthus caudatus agglutinin, Euonymus europaeus agglutinin and Arachis hypogaea agglutinin colocalized with DAergic neurons. Lectins affected the number, size or intensity of DAergic neurons,
reduced the mobility and affected the lifespan of C. elegans to different extents, with the SIS either
augmenting or mitigating the effects. Our observations are a tantalizing possible explanation for why
dietary plants have been linked to a risk of developing PD.
Study 2: Lifespan of C. elegans was increased by PJ treatment in wild type (N2, 56%) and daf-16
mutant (daf-16(mgDf50)I) (GR1307, 18%), by POMx in N2 (28%) and in GR1307 (10%), or by EA (11%).
PJ reduced intestinal fat deposition (IFD) in N2 (-68%) or in GR1307 (-33%). The IFD was increased by
POMx in N2 (137%) and in GR1307 (26%), by EA in N2 (66%) and in GR1307 (74%), or by UA in N2
(57%) and in GR1307 (43%). Both lectins and PJ are bioactive compounds, playing important roles in
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life. These studies may provide useful information for an alternative etiology of PD and offer solutions
of using PJ to delay aging and prevent obesity in humans.
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CHAPTER I. INTRODUCTION
1.1

General introduction
Dietary bioactive compounds such as phytochemicals, vitamins, minerals and fibers contained in

fruits and vegetables benefit humans and animals [1, 2]. Chemical compounds in fruits and vegetables
can alter gene expression; have neuroprotective and antiaging effects, and effects in preventing or treating
chronic diseases including cancer [3, 4].

Plant lectins were discovered over a century ago [5].

Consumption of lectins contained in seeds or tuber have caused diseases in human beings mainly due to
damage on intestinal mucosa [6]. Patients suffered vomiting and diarrhea after consuming a diet high in
red kidney beans containing the lectin phytohemagglutinin in a hospital in 1988 [7]. Lectins are also
related to disease symptoms in some patients with dysfunction of the immune system [8]. Recent studies
report that lectins play important roles in plant defense [9] and legume-rhizobial interactions [10].
Pomegranates (Punica granatum L.) have a high content of polyphenols (1.5%), including ellagic acid
(EA), gallic acid, anthocynidins, flavan-3-ols, straight chain fatty acids, citric acid, and malic acid.
Pomegranates consist of about 80% juice and 20% seeds with water (85%), and 10% sugars consisting
primarily of fructose (2.5 g to 17.6 g/100ml) [11, 12]. Dietary polyphenol antioxidants play important
roles in health [13-17]. PJ has been shown to extend lifespan in mice [18, 19] and Drosophila
melanogaster [20].
The increasing age of people in modernized countries creates a greater burden of chronic diseases
including cancer, cardiovascular disease, diabetes, and neurodegenerative disorders including PD and
Alzheimer's disease [21-25], leading to a high cost of health care and a great financial burden to the public
health system and families [26, 27]. The study of dietary bioactive compounds like lectins and PJ and its
derivatives in C. elegans organism may provide some useful information for an alternative possible
etiology of PD and offer some solutions to delay aging and prevent obesity in humans.

1

1.2

Dietary proteins may be trans-synaptically transported in the nervous system
Protein toxins are able to survive the harsh environment of cooking process, low pH of stomach,

and protease digestion of the GI track. Many of them can penetrate intestine epithelial cells and pass into
blood or lymphoid circulation [28-30]. Toxins are target specific. Botulinum neurotoxins (BoNTs) or
ricin can be trans-synaptically transported in the nervous system causing severe, even lethal damages on
humans and other mammals [31, 32]. Cholera toxin exerts toxicities only on the epithelial cells of intestine
and causes symptoms like watery diarrhea [33-35]; tetanus toxin (TeNT) affects neuromuscular junctions
after being taken up into blood or lymphoid circulation [36].
Glycoproteins and glycolipids are major components of eukaryotic cell membranes along with
phospholipids, and are the main binding receptors for toxins, playing a crucial role in the process of
binding and internalization [29, 37-39]. Glycoproteins and glycolipids are also essential compounds for
intercellular communications and reactions to alterations of the cell environment [40]. Both ricin and
some neurotoxins share similar A-B chain structure; in which chain A is responsible for recognizing
binding receptors and internalization, and chain B exerts toxicities. Understanding the underlying
mechanisms of neurotoxins may help better understand the effects of lectins on neurons.
1.3

Dietary plant lectins as an “unknown pathogen” in Parkinson’s disease
Higher prevalence of PD occurs in vegetarians compared to omnivores [41, 42], though

controversial. Plant lectins have been used for tracing neurons along nerve fibers in animal studies.
Dietary toxin proteins can overcome the barriers of digestion systems and cause severe, even lethal
damage on mammals including humans [31, 32]. We hypothesize that dietary plant proteins traverse the
GI wall, enter the nerve endings, undergo vesicular transport along nerve fibers, and damage DAergic
neurons as one etiology of PD. A recent Danish study showed that patients who had vagal nerves removed
20 years ago had a 40% lower incidence of PD [43], which supported our hypothesis of dietary plant
lectins.
2

PD is the second most common degenerative disorder of the central nervous system that impairs
motor skills and cognitive function, the main symptoms of PD are motion disorders, like muscle rigidity,
bradykinesia, and tremors [44]. Clinically, PD is characterized by the development of Lewy bodies due
to aggregation of a-synuclein (α-SYN) in the brain tissue and the partial loss of DAergic neurons in the
substantia nigra [45]. α-SYN also aggregates in microglia and further leads to PD although the detailed
mechanism remains unclear [46, 47], while astrocytes convert the PD-causing neurotoxin 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) to its active metabolite cation 1-methyl-4-phenylpyridinium
(MPP+) [48]. However, the mechanism of the formation of Lewy bodies is not clear [49]. The etiology
of PD is unknown but complex environmental factors play important roles for neurodevelopmental and
neurodegenerative disorders including PD [50, 51]. Results of large-scale epidemiological studies using
meta-analysis showed that a statistically positive association exists between PD and pesticide or herbicide
exposure [52]. Most of these pesticides share common features, such as the ability to induce oxidative
stress, mitochondrial dysfunction, α-SYN fibrillization and neuronal cell loss [53]. Insulin dysfunction
might be associated as a cause of PD though the detailed mechanism is still unclear [54]. Evidence
indicates that in Caenorhabditis elegans (C. elegans) high glucose concentration (14 mM) increases
aggregation of α-SYN while restricted glucose concentration reduces it [55].

Exposure to other

environmental factors such as solvents, metals and other pollutants are also associated with the risk of PD
in animal models [56, 57]. Despite the long-accepted viewpoint that environment and genetic factors
might be most related to the etiology of PD, a recent review in 2015 reported that dietary factors like
vitamins, flavonoids, calorie intake, caffeine, alcohol, and metals may also play a role [53, 58].
Plants contain glycoprotein-lectins (“non-immune sugar-binding proteins”) in seeds, fruits, and
nuts [59], that recognize and reversibly bind specific carbohydrates [60]. They are involved in plant
defense [9] and legume-rhizobia [10]. They resist gut enzymes maintaining function under adverse
conditions [61, 62]. They can penetrate the GI tract wall by endocytosis [63], probably by first binding a
3

carbohydrate lectin receptor [64] followed by endocytosis, and, astonishingly, can transfer transsynaptically in an antegrade and/or retrograde fashion along nerve fibers [60, 65]. Their medical
importance is increasingly being recognized by being conjugated with drugs for better drug absorption
from the GI tract [64, 66-68]. Particularly relevant to the current studies, lectins have been utilized
extensively for neuronal tracing studies [65, 69]. Ricin (Ricinus communis) as an extremely cytotoxic
lectin has been studied extensively for its function in retrograde transport. It is reportedly via a B-chain
mediated endocytosis, following a translocation of the enzymatically catalyzed A-chain, from the
endosomes to the Golgi apparatus [70, 71]. This property has been utilized for treatment of malignancies
at low doses [72, 73]. Lectins have also been conjugated with DNA for enhanced nervous system gene
delivery [74]. Most dietary plant lectins resist gut enzymes and maintain function under usually adverse
conditions for proteins [61, 62].
Most lectins are resistant to mild heat and protease [75], lectin concanavalin A (Con A) from
Canavalia seeds can survive high cooking temperatures such as 96 °C for up to three hours [76]. These
characteristics, theoretically, allow lectins to be ‘biologically active’ when reaching their “targets” in vivo.
Controversial reports suggest that a higher prevalence of PD occurs in vegetarians compared to omnivores
[41, 77].

The “Vegetarianism in America” study in 2015, published by Vegetarian Times

(vegetariantimes.com), shows that 3.2 percent of U.S. adults, or 7.3 million people, follow a vegetarianbased diet and 96.8 percent of U.S. adults or 220.8 million people are omnivores. A 2195 American
participants study reported that on average 1/3 of total vegetables people consumed were not cooked, and
people who consumed more raw vegetables also preferred raw fruits and grains [78]. Taken together, a
subgroup of dietary plant lectins may act as one of the long-term ‘pathogens’ that slowly cause cellular
inclusions of α-SYN.
The Amyotrophic Lateral Sclerosis / Parkinsonism dementia complex (ALS-PDS) in populations from
Guam, for example, has been linked to a diet rich in cycad seeds (Cycas micronesica) [79, 80]. The cycad
4

seeds contain ß−methylamino-L-alanine (BMAA) which has excitotoxic properties. Studies on human
brain tissue of ALS/PDC, ALS, Alzheimer’s disease, PD, Huntington's disease and neurological controls
indicated that BMAA is present in non-genetic progressive neurodegenerative disease but not in controls
or genetic-based Huntington's disease [81-84]. Animals fed with purified BMAA, however, do not show
ALS-PDS traits [85] suggesting that other mechanisms deliver toxin(s) to the target neurons. A newly
proposed medical hypothesis suggests that structurally similar glucosides of helicobacter pylori might be
accountable as neurotoxins [86] though currently unproven. Several lines of evidence suggest a possible
role of lectins in neuronal injury. First, lectins have been detected in Cycas revoluta, which is in the same
family (Cycadaceae), and genus (Cycas) as Cycas micronesica of Guam [87, 88]. Second, horses
consuming yellow star thistles (Centaurea solstitialis) show liquid necrosis in the substantia nigra and
develop nigropallidal encephalomalacia (NPE) symptoms, which are similar to human Parkinsonism. The
toxins responsible for NPE have not yet been identified [89]. These studies suggest that lectins might be
toxic or chaperone carriers of toxins in PD-like diseases.
1.4

Bioactive compounds of pomegranate juice and extracts improve lifespan in C. elegans
Dietary polyphenol antioxidants play important roles in health [13-17]. PJ has been shown to extend

lifespan in mice [18, 19] and Drosophila melanogaster [20]. PJ extract (POMx) potentiates lifespan
extension with dietary restriction, a finding attributed by polyphenols [18, 19]. POMx and PJ can also act
as prebiotics, having demonstrated antibacterial properties in vitro, and can block DNA repair and inhibit
proliferation of breast cancer cells (MCF-7) in vitro, as well as modulate the IGF-IGFBP axis [90-94].
POMx and PJ also down-regulate androgen-synthesizing genes to induce apoptosis of human prostate
cells (kappaB-dependent) in vitro and in mice in vivo [95-98]. POMx and PJ decrease prostate specific
antigen in humans after surgery or radiation [99, 100], inhibit tumor-associated angiogenesis in vitro and
in vivo [99], suppress inflammatory cell signaling in colon cancer cells [101] (50 mg/L PJ, in vitro),
improve memory [102] and improve fecundity in humans [20, 103-105].
5

As the main bioactive component, EA is a measure of the quality of PJ extract products [104, 106,
107]. EA in humans reaches a maximum plasma level in 1 hour (31.9 ng/ml), is eliminated within 4 hours
[108] and exerts an antioxidant effect [109]. Urolithin acid (UA) is the main active metabolite of EA and
is formed by colonic microflora. UA lasts longer in the human body than EA or other EA metabolites [91,
110], and has better bioavailability [111]. UA also suppresses colorectal, hepatic, and prostate cancers
synergistically with EA in vitro and in mice in vivo [112-116].
1.5
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CHAPTER II. DIETARY PLANT LECTINS MAY BE AN ‘UNKNOWN ETIOLOGY’ IN
PARKINSON’S DISEASE
PART A. DIETARY PROTEINS AND TRANS-SYNAPTICAL TRANSPORTATION
1.1

Introduction
Study of mechanisms of protein toxins and lectins has been conducted for decades, aimed at

elucidating the interesting phenomenon that a trace amount of botulinum neurotoxins (BoNTs) or ricin
could overcome the barriers of digestion systems and cause severe, even lethal damage to mammals
including humans [1, 2]. The targets of these toxins in humans vary. For instance, cholera toxin exerts
toxicities only on epithelial cells of intestine and causes symptoms like watery diarrhea [3-5]; but tetanus
toxin (TeNT) can cause further damages in neuromuscular junctions after being taken up into blood or
lymphoid circulation [6]. Several studies have investigated how these protein toxins or ricin survive the
harsh environment in the stomach and intestine including low pH and protease, and how the toxin
penetrate intestine epithelial cells into blood or lymphoid circulations [7-9]. Though some mechanisms
were revealed, the detailed mechanism of this process, especially the process of penetration into the
neuronal membrane is still under extensive research [10, 11]. Binding strength to neuronal membranes is
a prerequisite of the following translocations and other toxicities [12, 13].
Both ricin and some neurotoxins share similar A-B chain structure; in which chain A is responsible
for recognizing binding receptors and internalization, and chain B exerts toxicities. Other lectins can
recognize special binding sites on neuron membranes and then build communicating connections with
neurons. In this chapter, the travel of neurotoxins from intestine to central nervous system was covered
and the stress was placed on how neurotoxins were retrograde transported from axon to central nerve.
This part focused on protein toxins because of severe threat to human beings and have been more studied.
Understanding the underlying mechanisms would help design new drugs and better understand the effects
of lectins on neurons.
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1.2

Protein toxins

1.2.1 Botulinum neurotoxins and tetanus neurotoxin
1.2.1.1 Structure components
BoNTs and TeNT have been studied together in most cases because they share similar A-B chain
structures, employ similar pathways to exert toxicities; and attack neurons only [6, 14, 15]. BoNTs have
seven serotypes, including type A-G. The analysis of protein sequences of seven serotypes of BoNTs and
TeNT indicates sequence homology [16, 17]. In addition, BoNTs and TeNT cause similar symptoms of
paralyses because they both inhibit the release of neurotransmitter via zinc-dependent cleavage of protein
components [15]. The main difference between them is that BoNTs target neuromuscular conjunctions
while TeNT plays roles at neuron-neuron junctions.
Properties are determined by structures. In the wild with adequate moisture like in the soil, BoNTs
exist in the form of binding to a small complex called non-toxic neurotoxin-associated proteins (NAPs,
Figure 1), which is composed of Hemagglutinin (HA) and non-toxic non-HA (NTNHA) [18, 19].

Figure 1. Composition of BoNTs complex.
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The structure of NTNHA protein and BoNTs shows mirror symmetry so that they could bind tightly
with each other via multivalent bonds. This strong binding shield BoNTs from harsh environments like
low pH and proteases [20]. After surviving the harsh environment in GI tract and penetrating the GI wall,
BoNTs arrive at a moderate environment like blood or lymphoid circulation, where BoNTs are released
from the complex and at this time they can travel freely in vivo [21].
1.2.1.2 Neurotoxins absorbed from GI tract to circulation and up-taken to nerve endings
After surviving harsh intestinal environments, BoNTs need to overcome the intestinal barrier
before entering vascular circulation. Fujinaga et al. in 2013 reported that three steps were involved in
penetration through the intestinal epithelial barrier, including transcytosis, barrier disruption and
absorption from damaged barrier (Figure 2) [19]. In detail, two different pathways are involved in the
first step transcytosis. The first pathway is associated with the binding domain of the heavy chain, which
facilitates the binding and transcytosis of the whole toxin. BoNT/A mainly takes advantage of this
pathway; however, the detailed mechanisms underlying this pathway are still unknown. Couesnon et al.
proposed that Caco-2 and m-ICc 12 cells can absorb the binding domain of the heavy chain by a Cdc-42dependent and clathrin-independent pathway.

Recently, Couesnon et al. further proposed that

neuroendocrine intestinal crypt cells play an important role in transcytosis [22, 23]. The second pathway
is associated with HA, which could promote the binding of BoNTs with intestinal barrier due to its
carbohydrate-binding properties and the ability to transit the barrier. Fujinaga et al. reported that HA
plays an important role in facilitating the binding of BoNTs complex to the epithelial lining [24]. HA is
also involved in internalization of BoNT/C and BoNT/D complex into the intestinal epithelial barrier [25].
The third step is disruption of the epithelial barrier after BoNTs are transferred to the basolateral surface,
facilitated by HA. BoNT/A and BoNT/B would not cause some cytotoxic effects in epithelial cells during
the disruption [26], however, BoNT/C might do so [27]. The last step is release of BoNTs from the
damaged barrier into circulation.
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Figure 2. Three steps involved in the process of penetration into the intestinal epithelial barrier, including
transcytosis, barrier disruption and absorption from damaged barrier.
1.2.1.3 Internalization into neurons
After entering the blood or lymphatic stream, neurotoxins are transported to neuromuscular
junctions. Four steps are required for BoNTs and TeNT to enter neurons and exert toxicities (Figure 3).
After entering into neuron terminals, BoNTs’ effects are mainly restricted to the neuromuscular
conjunction, which prevents release of synaptic vesicles from cell membranes through three different
pathways as mentioned above; however, TeNT is retrograde transported to neuron soma in the spinal cord
and trans-synaptically transported to the axon of the next neuron [28].
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The first step is membrane binding, early research reported that BoNTs and TeNT bound to
gangliosides or glycosphingolipids which were found particularly in the outer leaflet of neuronal cell
membranes [29, 30]. Later studies suggested that BoNTs and TeNT bind to more than a single receptor,
and a dual-receptor theory was then proposed. Strong evidence for this dual-receptor theory is that the
binding of TeNT to rat brain membrane was greatly decreased but not abolished after protease
pretreatment, implying that other kinds of protein receptors are involved in binding. In detail, the dualreceptor theory proposed that BoNTs and TeNT bound to complex polysialogangliosides first, including
GD1b, GT1b and GQ1b, which are abundantly present on the outer leaflet of neuronal membranes;
thereafter, they further bind to more sparsely distributed protein receptor(s). Toxins accumulate first on
the membrane surfaces, and then further interact with protein receptors to complete the second step of
binding. Rummel described the detailed pathway of the first step in 2013 [31].
The second step is known as internalization, after toxins bind to the surface receptors, acid
compartments are formed with the endocytic process of toxins, where temperature and available energy
could affect this process [16].
The third step is translocation. After BoNTs and TeNT are transported to acidic compartments,
the compartments depart the internal cell surface and enter the cytosol. BoNTs and TeNT utilize different
pathways for translocation from compartments into cytosol. Due to the low pH in the compartments, the
L chain of the BoNTs would be rearranged; leading to higher hydrophobicity, which makes it easier to
traverse the lipid bilayer [16, 32]. By this step, the light chains of BoNTs are freely available in the cytosol
of the neuron cells.
The fourth step is intracellular action, which mainly inhibits the release of neurotransmitters from
neurons into neuromuscular junction. As shown in Figure 3, the L chain of the toxin cleaves essential
proteins necessary for the release of neurotransmitters.
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Figure 3. Four steps involved in the internalization and toxic effects.
1.2.2 Shiga toxin
Shiga toxin inhibits protein synthesis in target cells [33]. Globotriaosylceramide (Gb3), the special
glycolipid receptor recognized by shiga toxin, was first isolated from both HeLa cells and rabbit jejunal
mucosa [34]. Shiga toxin has two sub-types; Stx1 and Stx2, both of which feature A-B5 structure, where
one A-subunit is the active component and five B-subunits are responsible for binding [35]. Stx2 causes
more severe damage than Stx1 which only causes some infections [36-38].
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Gb3 was first found in the rat sensory neurons and in rabbit brain capillaries by
immunohistochemistry [39]. Takahashi, K. first reported that Stx2 might damage neuron cells indirectly
using a rabbit model [40]. Other studies reported that Stx2 induced a glial lamellipodia-like process
between presynapse and motoneuronal soma, and proposed that neurons were the primary target of Stx2,
which could lead to paralysis [35]. Stx2 was further reported to induce expression of Gb3 in neurons and
cause dendritic abnormalities in rat brains [41], and to exert direct cytotoxic effect in the thalamus in rats
[42].
Shiga toxin employs a clathrin dependent mechanism to enter the cell, binding to glycolipid ligand
and endocytosed from coated pits [43, 44]. Binding sites are randomly located on cell membranes, but if
the temperature reaches 37 ℃, the binding site Gb3 will concentrate in coated pits. Binding of the subunit
B to Gb3 causes induction of narrow tubular membrane invaginations, which drives formation of inward
directed membrane tubules for bacterial uptake into the cell. These tubules are essential for the uptake of
shiga toxin into host cells [45].
To sum up, neurotoxicity of shiga toxin is mainly due to the subtype Stx2. Gb3 is the primary
receptor on neuron cell membranes that bound to Stx2, however, the detailed mechanism of binding and
the following internalization is still not clear.
1.3

Lectins

1.3.1 Ricinus communis agglutinin (RCA)
Ricin, synthesized and stored in the endosperm cells of maturing Ricinus communis seeds (castor
beans) is a heterodimeric plant protein that has emerged as the first well-known lectin due to its extremely
high toxicity of trace doses and its special A-B chain structure [46, 47]. Similar to BoNTs and TeNT,
ricin utilizes the A-B mechanism to penetrate cell membrane. Chain B of ricin attaches to the cell surface
first and then the protein undergoes endocytosis into cells. Ricin inhibits the synthesis of protein
enzymatically after its chain A enters cytosol and removes a specific adenine residue from the 28S
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ribosomal RNA (28SrRNA) of the large subunit of eukaryotic ribosomes [48], other toxins share the
similar mechanisms include diphtheria toxin, Shiga toxin, Pseudomonas exotoxin A, abrin and modeccin
[49].
Chain B has special binding sites for galactose [50]; galactose exists in many cell membranes
because it is widely present in glycoproteins and glycolipids, which are the major components of cell
membranes [51], thus ricin is bound to the cell surfaces. Other cell surface receptors include Nacetylgalactosamine, glycoproteins, glycolipids or mannose receptors [52]. After chain B successfully
binds to cell surfaces, ricin utilizes both clathrin-dependent and clathrin-independent pathways including
caveolae and macropinocytosis to enter cells [53-56]. Ricin mainly utilizes clathrin-coated pits to be
internalized, but if this pathway is blocked, ricin could still be endocytosed by clathrin-independent
pathways [57]. Catherin-dependent mechanisms are well studied, which is a receptor-mediated uptake of
proteins. Special protein motifs like tyrosine residue in the cytosolic tail of the receptors is necessary for
the uptake in this mechanism [57, 58]. In detail, chain B of ricin is binding to the galactosyl-residues in
cell surface and then internalized [59]. Clathrin-independent mechanism was proposed based on the
finding that clathrin-dependent endocytosis was inhibited by transfection of Cos-7 cells with a mutant of
the 100~kDa GTPase dynamin, whereas fluid-phase uptake still happened [57, 60], this suggests that
clathrin-dependent pathway is not the only pathway that ricin employed. The endocytosis of ricin is
reduced to about 50% when the clathrin-dependent pathway is inhibited [61].
Ricin’s toxicity largely depends on the exposure route, ingestion mainly caused mass fluid loss by
producing mucosal injuries, but injection would cause severe damage by inhibiting the synthesis of
proteins in cells [62]. Ricin is able to be transported from peripheral nerves to neurons retrograde, called
‘suicide transport’ [63]. Rat studies showed that 0.2 microgram of ricin caused heavy fiber degeneration
in the sciatic nerve proximal to the injection site, but not in a nearby tributary nerve [64], which suggested
that ricin can produce a selective and severe lesion by retrograde "suicide transport". Injection of ricin
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bilaterally in the sciatic nerve in rats induces the loss of motor neurons, leading to lower limb paralysis
and the deficits that occurs in diseases like amyotrophic lateral sclerosis (ALS) and infantile progressive
spinal muscular atrophy (SMA) [65, 66]. Ricin also affects the glial cells in addition to the degeneration
of motor neurons in rats. Injection of ricin into rat facial nerve causes the degeneration of facial motor
neurons, local microglial cells respond to nerve crush by rapid proliferation and phagocytosis of neuronal
debris. After nerve crush, the expression of glial fibrillary acidic protein by fibrous astrocytes is enhanced
[67]. Intact ricin is resistant to heat, freezing and proteolysis [68]. These findings suggested a possible
route for lectins to transport from peripheral nerves to the central nervous system, which supports the
hypothesis that dietary plant lectins might affect DAergic neurons and be one potential cause of PD.
1.3.2 Wheat germ agglutinin (WGA)
WGA is a plant lectin that has been employed as an anterograde tracer research tool for years. WGA
has a unique binding affinity for N-Acetylneuraminic acid, a key component of neuronal membranes
found in the brain, such as gangliosides which have diverse roles such as cell-to-cell contact, ion
conductance, as receptors. WGA also attaches to the protective coating on the nerves known as the myelin
sheath [69]. The presence of N-acetylglucosamine inhibits interactions between WGA and cell surface,
implying that WGA could bind to N-acetylglucosamine on cell surfaces [70].
WGA is endocytosed by nonfenestrated endothelia throughout the central nervous system, WGA
passes through the blood brain barrier (BBB) through a process called “adsorptive endocytosis”, this
adsorptive endocytosis was proposed to associate with inclusion of Golgi complex [71, 72]. WGA is
uptake via adrenergic nerve terminal and then transported retrograde to the superior cervical ganglion [73],
however, the detailed mechanism is not clear and it is suggested that WGA has a single population of
binding sites.
Most recently, Damak, et al. reported that WGA was transported to the geniculate and petrosal
ganglia, and proposed this uptake and transportation was via across synapses in vesicles [12]. This
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suggested that WGA bind to N-acetylglucosamine or N-Acetylneuraminic acid on cell surfaces first to
build some connections, and then by an unknown pathway, WGA is able to form a small channel on the
cell membrane, followed by formation of vesicles.
1.3.3 Phaseolus vulgarwas leucoagglutinin (PHA-L)
PHA-L has been used as an anterograde tracer of pathways of the central nervous system for a long
time, even though it also shows some extent of retrograde transport [74-78]. In mammals, PHA-L is
mainly anterograde transported through the nerve system, but some studies reported that PHA-L
demonstrated almost the same degree of anterograde and retrograde transport in frogs, which might be
due to different distribution of binding sites on cell membranes between frog and mammals [79].
1.3.4 Concanavalin A (Con A)
Another interesting lectin is Con A, which can bind to neuronal and synaptic membranes extensively
[80], but the uptake of this lectin is very limited [73]. Similar to WGA, Con A has also been widely
employed as a tool to study retrograde transport for its special property [81-83]. Con A is taken up by
adrenergic nerve terminals and transported retrograde to the superior cervical ganglion [73]. The binding
pattern of Con A suggests that the ability of binding to the cell membranes cannot guarantee following
internalization; the effective action is a very complicated process requiring several parts to cooperate. The
binding site of Con A was confirmed by pre-incubation of Con A with mannose which could greatly
decrease Con A activity [84].
In addition to these lectins, other lectins also have shown the ability of recognizing or binding to
neurons and their accessories. In recent years, the unique properties of binding to carbohydrate receptors
have made lectins powerful research tools for characterizing the distribution of binding sites on cell
surfaces.
In 1985, Fabian, R. H. reported the axonal and transneuronal transport of lectins including WGA,
Pisum Sativum Agglutinin (PSA), Lens Culinaris Agglutinin (LCA), Soybean Agglutinin (SBA), and Con
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A, and proposed that axonal and transneuronal transport of the lectins likely depended upon their
respective carbohydrate affinities [83].
Silverman reported utilization of plant lectins to study carbohydrates on sensory ganglion cell
surfaces [85]. In rats, the alpha-D-galactose-specific Griffonia Simplicifolia I-B4 [86] lectin was used to
characterize galactose-terminal glyco-conjugates on a large subpopulation of small neurons, peripheral
autonomic, gustatory and visceral sensory, enteric neurons, and the accessory olfactory bulb. L-fucosebinding Ulex europaeus-I (UEA) lectin was used to label the substantia gelatinosa in the human spinal
cord. In rabbit, a small sensory ganglion cell subset and the spinal cord substantial gelatinosa was colabelled by both the GSA and UEA lectins [85]. Other research reported use of eight lectins including
Con A, Arachis hypogaea agglutinin (PNA), Soybean Agglutinin (SBA), Dolichos Biflorus Agglutinin
(DBA), Phytolacca americana (PWA), WGA, UEA and PHA from six groups to study the lectin binding
sites of olfactory receptor neurons, and all of them demonstrated their special binding properties [84]. The
reveal of sugar-binding site of Con A has facilitated the mechanism research [87].
1.4

Discussion
The structure of neurotoxins and lectins play a key role in the binding and interactions with neurons.

Special structural characteristics have determined their inherent properties of recognition, binding and all
other effects. A-B structure is the most common structure in neurotoxins, in which subunit B is
responsible for binding while subunit A for toxic effects. The receptor on cell membranes is another
important factor that affects the interactions. For lectins, special receptors on cell membranes determine
which lectins they can bind to and the intensity of the interactions, but the detailed mechanism is not all
known. Other factors may also affect this binding and internalization, for example, cytofluorometric
quantification study demonstrated that regenerated nerve greatly increased the uptake of Con A and WGA
in mice [63].
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However, due to the potent toxic effects and great value of research, it is of high necessity to
illuminate the mechanism as well as the pathways of these neurotoxins and lectins. Many researchers
have been working on the mechanisms and applications of these neurotoxins and lectins, but more efforts
will be needed. For example, the mechanisms of the action of Shiga toxin and some lectins are still very
vague. Research on lectins has focused on the characterization or monitoring the sugar receptors on cell
membranes including cancer cells, some studies have started to investigate physiological effects of lectins
[88, 89]. In a rat study, after oral administration of ricin, the ricin was absorbed from GI tract into blood
and lymphatic circulation and detected in the liver and spleen [90]. This finding together with ricin’s
ability of ‘suicide transport’ might suggest that ricin have the ability of traversing the GI tract to enter the
central nervous system, which supports our hypothesis that dietary plant lectins may have some effects on
neurons. The etiology of PD is still not well defined, but the information presented here provides an
alternative possibility of inducing PD.
1.5
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PART B. DIETARY PLANT LECTINS APPEAR TO BE TRANSPORTED FROM THE GUT
TO GAIN ACCESS TO AND ALTER DOPAMINERGIC NEURONS OF C. ELEGANS1
1.1

Introduction
Could dietary plant proteins, such as lectins, traverse the gut intact, with vesicular transfer to neurons

and be transported intact along axons to affect DAergic neurons as one etiology of PD? A recent Danish
study showed that patients who had vagal nerves removed 20 years ago had a 40% lower incidence of PD
[1]. Some reports claim that vegetarians have higher rates of PD [2, 3]. This research uses C. elegans as
a model to investigate dietary lectins transport to DAergic neurons.
PD is the second most common degenerative disorder of the central nervous system that impairs
motor skills and cognitive function, the main symptoms of PD are motion disorders, like muscle rigidity,
bradykinesia, and tremors [4]. A human study with 490 PD patients and 176 health volunteers showed
that the age is a key factor to the severity of the disease on a motor scale, but shows no difference in nonmotor symptoms, and in men, the phenotype is characterized by upper-body disease while in women by
postural dysfunction [5]. A survey of 210 PD subjects reported that in general men suffer more than
women from PD symptoms according to the index of quality of life [6]. Other survey studies reported
that men are at higher risk of getting PD than women [7-11]. A study of 1,741 subjects compared motor
and non-motor symptoms between male and female subjects according to their age of symptom onset and
diagnose, no difference was found between male and female except that women do better than men in
non-motor symptoms [12]. The incidence of PD in Italian was estimated at 380/100,100 in year 2011 by
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analyzing drug prescriptions, tax-exemptions as well as hospital discharge records [13]. Longer lifespan
has resulted in heavy societal financial burden and emotional burden all over the world [14].
Clinically, PD is characterized by the development of Lewy bodies due to aggregation of asynuclein (α-SYN) in the brain tissue and the partial loss of DAergic neurons in the substantia nigra [15].
α-SYN also aggregates in microglia and further leads to PD though the detailed mechanism remains
unclear [16, 17]. Astrocytes convert neurotoxin MPTP to its active metabolite MPP+ [18]. However, the
mechanism of the formation of Lewy bodies is not clear so far [19]. To date, PD cannot be cured though
some treatments may alleviate the symptoms. The etiology of PD is unknown but complex environmental
factors play important roles for neurodevelopmental and neurodegenerative disorders including PD [20,
21]. Results of large-scale epidemiological studies using meta-analysis showed that a statistically positive
association exists between PD and pesticide or herbicide exposure [22], most of these pesticides share
common features, such as the ability to induce oxidative stress, mitochondrial dysfunction, α-SYN
fibrillization and neuronal cell loss [23]. Insulin dysfunction might be associated with the cause of PD
though the detailed mechanism is still unclear [24]. Evidence indicates that in C. elegans high glucose
concentration (14 mM) increases the aggregation of α-SYN while restricted glucose concentration reduces
it [25]. Exposure to other environmental factors such as solvents, metals and other pollutants are also
associated with the risk of PD in animal models [26, 27]. Despite the long-accepted viewpoint that
environment and genetic factors might be most related to the etiology of PD, a recent review in 2015
reported that dietary factors like vitamins, flavonoids, calorie intake, caffeine, alcohol, and metals also
play an important part in the rise and development of PD [23].
Plant lectins were discovered over a century ago (see review [28]). Toxicity of lectins was first
recognized, independently, by Bruylants and Vennemann [29], Warden and Waddell [30] (described by
Carl Oppenheimer [31]), and Dixson [32]. Lectin’s hemagglutination property was found by Stillmark in
1888 [33], and a general antigenicity of lectins was revealed by Paul Ehrlich in 1890 [34] who won a
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“Nobel Prize in Physiology or Medicine 1908” “in recognition of their work on immunity”
(http://www.nobelprize.org/nobel_prizes/medicine/laureates/1908/).

Thereafter, lectins’ “immunity”

(mainly hemagglutination of red cells for antigen typing) was used for immunological research (see
Textbook of Military Medicine [35]). In 1919, Sumner crystallized (Canavalia ensiformis, Concanavalin
A) [36]. A half century later, investigators began to determine ABO-blood subtypes due to their sugarbinding properties, and the word “lectins” was formally coined [37, 38]. Recent studies report that lectins
play important roles in plant defense (see review by [39] and legume-rhizobial interactions [40].
Plants contain glycoprotein-lectins (“non-immune sugar-binding proteins”) in seeds, fruits, and
nuts [41], and recognize and reversibly bind specific carbohydrates [42]. They are involved in plant
defense [39] and legume-rhizobia [40]. They resist gut enzymes maintaining function under adverse
conditions [43, 44]. They can penetrate the GI tract wall by endocytosis [45], probably by first binding a
carbohydrate lectin receptor [46] followed by endocytosis, and, astonishingly, can transfer transsynaptically in an antegrade and/or retrograde fashion along nerve fibers [42, 47]. Their medical
importance is increasingly being recognized by being conjugated with drugs for better drug absorption
from the GI tract [46, 48-50]. Particularly relevant to the current studies, lectins have been utilized
extensively for neuronal tracing studies [47, 51].
Most dietary plant lectins resist gut enzymes and maintain function under usually adverse
conditions for proteins [43, 44]. Lectins have effects in both pathological and normal processes in living
organisms due to their carbohydrate-binding properties [52]. Non-toxic lectins, such as tomato lectin and
wheat germ agglutinin, are suggested to show growth factor activity in the GI tract [43]. Bacteria or
parasitic protozoa, through their own lectins, attach to carbohydrate receptors on epithelial cells to
colonize the GI and urinary tracts. Some lectins are synergistically toxic both locally and systemically to
experimental animals [43]. Kidney bean lectin (PHA), for example, damages intestinal epithelial cells,
causes bacterial overgrowth, and induces nutritional disorders, effects which are preventable by specific
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inhibiting sugars that have competitive binding capacities to lectins by sharing similar terminal structures
[43, 53].

Likewise, dietary saccharides or glyco-conjugates, such as probiotic agents and milk

oligosaccharides, may act as receptor analogs or decoys to selectively and competitively reduce lectin
binding [43, 54, 55]. Soybean lectin has shown potential anticarcinogenic effects [56].
Lectins are widely available in seeds, fruits or nuts of fruits and vegetables. A 2195 American
participants study reported that on average 1/3 of total vegetables people consumed were not cooked, and
people who consumed more raw vegetables preferred raw fruits and grains [57]. People in different
regions of the world have their own preference in consuming certain raw or cooked vegetables, some
vegetables like tomatoes, sprout soybeans and carrots are more consumed raw, but other vegetables like
peas are more consumed cooked [57]. Many studies have investigated anticarcinogenic effects of fruits
and vegetables. For example, high consumption of fruits and vegetables is negatively related to the
incidence of cancer in the GI tract [58, 59]. Leafy vegetables have beneficial effects in preventing the
development of breast cancer [60]. However, consumption of citrus fruits does not have beneficial effects
on stomach cancer [61]. Human cell membranes have different glycoproteins and carbohydrates due to
membrane differentiation [62], which may make some people more vulnerable than others. Elder people
cannot tolerate raw vegetables as well as cooked vegetables; main symptoms of intolerance include
diarrhea and vomiting [63]. Interesting, the prevalence of PD is higher in elder people than in young [64].
Taken together, all this information suggest that people are exposed to lectins daily as they consume
varieties of fruits and vegetables, raw or cooked.
Consumption of fruits or vegetables has been reported to cause diseases in human beings mainly
due to the damage of lectins on intestinal mucosa [65]. Patients suffered vomiting and diarrhea after
consuming a diet high in red kidney beans containing lectin PHA in a hospital in 1988 [66]. Lectins are
related to the disease symptoms in some patients with dysfunction of autoimmune system [67]. Overall
lectins can be found in about 30% of all the food [67]. The content of lectins in dietary plants vary among
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different plants (Table 1). The content of lectin Con A is as high as 15 mg/gram of seeds, the content of
lectin UEA I is 0.045 mg/gram. The food content of lectin LcH, EEA, CSA and DBA is not available.
Table 1. Summary of lectins contents from literature search
Lectins
UEA I
PSA
PHA
PNA
GNA
AIA
STA
ACA
WGA
SBA
GSL I
Con A
CPA

Amount (mg/g)
0.045 [68]
0.28 – 0.65 [69]
1.07 [70]
2 [71]
2.5 [72]
7.2 [73]
8 [74]
1.7 [75]
0.16 [76]
0.2 [77]
0.4 [78]
15 [79]
0.5 [80]

Comments
seeds
seeds
seeds
seeds
bulb tissue
seeds
tuber
seeds
wheat germ
seeds
seeds
seeds
Seeds

Direct evidence of neuronal damage caused by daily exposure to dietary plant lectins is not
available so far. Consumption of vegetable products, however, is a common factor in the epidemiology
of PD-like diseases. The Amyotrophic Lateral Sclerosis / Parkinsonism dementia complex (ALS-PDS)
in populations from Guam, for example, has been linked to a diet rich in cycad seeds (Cycas micronesica)
[81, 82]. The cycad seeds contain ß−methylamino-L-alanine (BMAA) which has excitotoxic properties.
Studies on human brain tissue of ALS/PDC, ALS, and Alzheimer’s disease, PD, Huntington's disease and
neurological controls indicated that BMAA is present in non-genetic progressive neurodegenerative
disease but not in controls or genetic-based Huntington's disease [83-86]. Animals fed with purified
BMAA, however, do not show ALS-PDS traits [87] suggesting that other mechanisms deliver the toxin(s)
to target neurons.
In equine Parkinsonism, consuming yellow star thistles (Centaurea solstitialis) or Russian
knapweed (Acroptilon repens) causes liquid necrosis in the substantia nigra pars reticulata and the globus
pallidus by destroying DAergic neurons, developing NPE, and creating histopathological features which
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resemble human idiopathic PD [88]. These observations suggest transport of toxic substances to neurons.
To date, however, epidemiology has not proven dietary lectins to have a significant impact on neuronal
degenerative diseases in humans.
Signature pathologies of PD, e.g., Lewey bodies and aggregated α-SYN occur in neurons of the
enteric nervous system of the GI wall, in addition to the neurons of the central nervous system (CNS) [89].
The findings reported here support Braak and Hawkes’ hypothesis that the GI tract may be a potential site
of neuronal invasion by an “unknown etiologic agent”, potentially responsible for causing some
percentage of PD [89-93]. Braak and Hawkes’ hypothesis was based on the finding that α-SYN
immunoreactive inclusions were found in neurons of the submucosal Meissner plexus, whose axons
project into the gastric mucosa and terminate in direct proximity to fundic glands. These elements
provided the first link in an uninterrupted series of susceptible neurons that extend from the enteric to the
central nervous system. The existence of such an unbroken neuronal chain lent support to the hypothesis
that a putative environmental pathogen capable of passing the gastric epithelial lining might induce αSYN misfolding and aggregation in specific cell types of the submucosal plexus and reach the brain via a
consecutive series of projection neurons. It is suggested herein that one possible etiologic agent could be
lectins.
Several animal models have been developed to investigate the etiology and the underlying
molecular mechanisms of PD. Neurotoxic models have been most studied and adopted, which are mainly
using 6-hydroxydopamine (6-OHDA), MPTP/MPP+ or rotenone to induce PD-like motor symptoms in
animals. Neurotoxic models share similar mechanisms of inhibiting the level of complex I of the
respiratory chain, which further leads to the apoptosis of DAergic neurons [94]. Genetic models
specifically modify certain genes that are related to the etiology of PD. The main limitation of genetic
models is that the detailed mechanisms for the effects of genes are still at large though some models have
shown effects.
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C. elegans as an animal model to study PD was first reported in 2001 [95], and has been widely
used [96-101]. C. elegans has a high conservation (>65%) of human disease-associated genes [102, 103].
A total of eight DAergic neurons in the hermaphrodite C. elegans [104-106], respond to signals from
environmental mechano-sensory stimuli, e.g. exhausted food supply, which has offered molecular, genetic,
and behavioral tools to aid human disease studies [107-111].
C. elegans modulates locomotion behavior by using dopamine and serotonin to mediate motor
circuits in chemical synapses, gap junctions, and neuromuscular junctions [112-114]. Intestinal muscle
cells are innervated by pharyngeal motor neurons and DAergic neurons via the preanal ganglia. Structures,
sensory-motor synapses, gap junction contacts, and activities all resemble those in the mammalian GI
tract [115, 116]. A typical phenotype of PD in C. elegans caused by the degeneration of DAergic neurons
is the slowness of the mobility. In liquid culture, 0.5 mM of MPP+ induces significant degeneration of
DAergic neurons and reduces the mobility of C. elegans [97, 99]. Due to the automated devices and
advanced software, tracking and analyzing the mobility of large number of C. elegans at the same time is
possible today.
In this study, features of the GFP-dopamine transporter fusion protein C. elegans (egIs1[Pdat1::GFP]) were evaluated by the numbers, fluorescent intensity, and sizes of GFP-DAergic neurons.
Meanwhile, TRITC/rhodamine labeled lectins were also followed post-feeding, to establish the ability of
lectins to bind or penetrate the GI wall or nerve cells. The question was whether dietary plant lectins can
impair or alter apparently lectin-targeted DAergic neurons. Differences in inherited sugar structures of
gut and neuronal cell surface may make some individuals more susceptible in this conceptual disease
model. The effects of lectins on the mean lifespan and the movement distance and velocity in liquid
culture in C. elegans were also evaluated. Our results support Braak and Hawkes’ hypothesis suggesting
one alternate potential etiology of PD.
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1.2

Materials and methods
C. elegans egIs1[Pdat-1::GFP] that express GFP in the 8 DAergic neurons [117, 118] and the

standard food Escherichia coli (E. coli) were obtained from C. elegans Genetics Center (CGC, MN). The
C. elegans model does not require regulation of the Institutional Animal Care and Use Committee
(IACUC).
1.2.1 Culture Escherichia coli (E. coli, OP50)
OP50 were cultured by the standard method described elsewhere [119]. Briefly, approximately 10
µL of stock E. coli solution was added to media and incubated at 37°C for 24h. The OP50 were then
plated in PetrifilmTM (3M Corporate, St. Paul, MN) at 37°C for 24h until densities of 5×108 to 5×1011
colony forming units (cfu/ml) were reached and then were fed to the C. elegans ad libitum [119, 120]. The
OP50 stock feeding solution was enriched to 2×109cfu/ml by centrifuging at 2,200 g for 10 minutes and
washed with S-complete buffer twice.
1.2.2 C. elegans culture
Mature gravid transgenic C. elegans egIs1[Pdat-1::GFP] were treated with NaOH (1M) and sodium
hypochlorite solution (5.25%, 5:2 ratio) to dissolve the body and release viable eggs [119]. The eggs were
hatched overnight fed ad libitum with LB broth (200 µL/well) containing OP50 5x108 – 5x1011 cfu/ml
[121], after washing with S-complete solution 3 times. The age-synchronized C. elegans were diluted to
100 animals/ml, plated in liquid culture in a 96 well plate (120 μL/well, 10-15 animals) [122]. The plate
was tape sealed, bagged, and covered with aluminum foil to avoid contamination. All animals were kept
in a 20C low temperature incubator (Revco Tech., Nashville, NC, USA) throughout the experiments.
Thirty microliters of 5-Fluoro-2′-deoxyuridine (FUDR, 0.6 mM) solution was added to each well at larvae
4 stage.
All treatments were applied at day 3 after hatching. Four dose responses of twenty lectins were
obtained for each culture condition in a dark room. Control animals were fed with OP50. Experimental
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groups were fed rhodamine/TRITC-conjugated lectins. The lectins were incorporated into feeding
medium with OP50. Concentrated OP50 were added to each well every other week throughout the
experiment. Each group of nematodes was collected and fixed after the first week for the liquid culture
as described elsewhere [123]. Briefly, after being collected from wells, animals were washed with SBasal twice, fixed with paraformaldehyde (4%) over 2h at 4°C and washed with PBS for 5min x 3. Ten
microliters of Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL) was applied to a
glass slide followed by 10 µL of the medium containing C. elegans. At last, a cover glass was mounted
on the glass slide.
1.2.3 Select lectins
Commercially available plant lectins conjugated with TRITC or rhodamine were purchased from
EY labs (San Mateo, USA), Vector Labs (Burlingame, USA), or Sigma-Aldrich (St. Louis, USA). All
tested lectins were selected from dietary plants or vegetables. The doses of lectins were determined based
on previous studies, literature search or recommendations from product specifications.
1.2.4 Average probability of survival (APS) assay
All average probability of survival (APS) assays were conducted in liquid culture (96-well plate).
The animals were synchronized and seeded into each well of a plate (n=10-15) and OP50 was added to
each well. Thirty microliters (0.6mM) fluorodeoxyuridine (FUDR) was added to each well and then the
plate was shaken evenly to sterilize the animals. Four different treatments (50 µL/treatment, n=6 row)
including control or serial of lectins were added. The plate was then covered with aluminum foil. The
whole procedure was performed in a dark room to prevent bleaching of fluorophores. After the plate was
shaken for 3 minutes, the survival animals were counted every other day until all were dead under an
inverted microscope (Nikon, Eclipse Ti –S, Japan) at 4x or 10x magnification. Animals were exposed to
strong lights to stimulate the movements [124] and the movement of pharynx was checked to confirm
whether the animals were dead when they were not moving.
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1.2.5 Mobility analysis
Mobility analysis was conducted in a 96-well plate. Animals of larvae 1 stage were seeded into the
plate with about 20 animals per well. Each well was treated with MPP+ (0.5 mM) [97] or different lectins.
All the tested lectins were listed in Table 2. The plate was kept in a low temperature incubator (20°C) and
analyzed 48 hours later. After about 2 minutes of agitation, the plate was placed on the stage of the
microscope (Nikon, Eclipse Ti –S, Japan). Using a digital camera, a video of the C. elegans (n=20-25)
with 20 frames (1 frame/second) was acquired from each well and images stored for offline analysis. The
video clips were analyzed by tracking the movement of animals using NIS-Elements Advanced Research
(version 3.22.11). The distance and the velocity of the movement were used as a function to characterize
the effects of lectins on the mobility of C. elegans. Quantitative indicators were used to compare the
mobility indicators between treatments and the control.
Table 2. List of lectins tested in mobility assay
Lectin
ACA
PSA
S-WGA
GNA
SBA

Dose
(µM)
0.032
0.043
0.046
0.077
0.017

Lectin
EEA
UEA I
AIA
GSL I
Con A

Dose
(µM)
0.048
0.033
0.031
0.018
0.019

Lectin
PNA
WGA
CSA
HHA
CPA

Dose
(µM)
0.018
0.046
0.065
0.04
0.047

Lectin
PHA-E
LcH
DBA
PHA-L
STA

Dose
(µM)
0.017
0.05
0.018
0.017
0.02

1.2.6 Fluorescent microscopy
The GFP-DAergic neurons were identified by FTIC filter (480Ex/520Em) and the number of GFPDAergic neurons counted. Fluorescent intensity of GFP-DAergic neurons and their average sizes (µm2)
were determined by NIS-Elements Advanced Research (version 3.22.11) and compared between the
control and lectins group. Briefly, a picture was taken for each animal under the FITC filter, in which the
GFP-DAergic neurons were visible. A circle was first drawn around each GFP-DAergic neuron and then
the software measured the area and fluorescent intensity automatically.
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Fluorescent intensity of

rhodamine-lectins was determined by a TRITC filter (580Ex/620Em) to assess co-localization. The
magnitude of the effect(s) of the lectin on the DAergic neurons, the number, fluorescent intensity (arbitrary
unit), and sizes (µm2) of GFP-DAergic neurons were determined and compared among each group. Colocalization was initially identified with an inverted microscopy (Nikon, Eclipse Ti –S, Japan) and then
confirmed at a Z-axle with laser scanning microscopy (Leica, TCS SP5, Germany).
1.2.7 Solutions and chemicals
Standard NGM agar plates (g): NaCl 3.0g, Bacto-agar (Becton, MD) 20g, Bacto-peptone 2.5g
(Becton, MN), Cholesterol solution 0.1% (0.005/ml 95% ethanol), and dH2O 975ml were mixed.
Additions to the autoclaved solution (M): CaCl2 1.0 1ml, MgSO4 1.0 1ml, KPO4 pH6 1.0 25ml. LB Broth:
25.0g, dH2O 1L (autoclave). S-basal solution (M): NaCl 0.1, KPO4 pH6 0.05, Cholesterol 0.1%, was
autoclaved. PBS (mM): 115 NaCl, 75 Na2HPO4•7H2O, and 7.5 KH2PO4, pH 7.4.
1.2.8 Statistical analyses
All results are presented as mean ±S.E.M. Analyses were carried out using SAS/STAT® software,
Version 9.4 of the SAS System for Windows (Cary, NC, USA). Survival curves were displayed by
binomial probabilities obtained from logistic regression models as surrogates for survival probabilities
and mean lifespan was estimated via Kaplan-Meier (log-rank). ANOVA models were used to analyze
neuron data. For each group, 10-15 animals were analyzed for liquid culture. Motion activity analysis
was performed by Systat software (version 12.5, SigmaPlot for Windows, San Jose, CA, USA). The
normality of the data was evaluated before further analysis, nonparametric analysis Kruskal–Wallis with
Dunn’s method was used to compare between treatments and the control group if the assumption of
normality was not met. An alpha level of 0.5 was considered statistically significant.
1.3

Results
Diets supplemented with varying concentrations of TRITC-conjugated lectins ACA, EEA and PNA

in liquid culture were fed to C. elegans, and subsequently detected by fluorescence microscopy to be
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associated with GFP-DAergic neurons (Table 3). The only explanation for this observation is that these
TRITC-labeled lectins traveled in some manner from the gut to the GFP-DAergic neurons. We observed
that some lectins had the following effects: a) altering the number of DAergic neurons, b) decreasing
fluorescent intensity of GFP-expressing neurons (less GFP-dopamine transporter), or c) altering neuron
size. Other seventeen lectins (Table 4) were not observed to be transported to GFP-DAergic neurons, but
most of them affected the size, area or intensity of DAergic neurons to different extents, possibly
indicating that undetectable amounts of these lectins caused the effects, or that some unexplained
secondary effect of the lectins caused those “pathological effects”. In addition, the effects of tested lectins
on the mean lifespan of C. elegans in liquid culture were evaluated. Lectins affected the mean lifespan of
C. elegans in different manners. PHA-E, PSA, UEA I and WGA increased the mean lifespan (P<0.05).
ACA, EEA, PNA, AIA, CSA, DBA, GNA, GSL I, HHA, PHA-L and SBA reduced the mean lifespan
(P<0.05). LcH and S-WGA reduced the mean lifespan at low dose but increased it at high does (P<0.05).
Con A, CPA and STA did not affect the mean lifespan significantly (P>0.05). In mobility assay, larvae 1
stage of C. elegans were fed with different lectins. The results of mobility assay demonstrated that all
tested lectins reduced both movement distance and velocity of C. elegans in liquid culture compared with
the blank control group (OP50 only, P<0.05).
1.3.1 Lectins co-localized with the GFP-DAergic neurons
There lectins ACA, EEA and PNA were observed to co-localize with GFP-DAergic neurons in C.
elegans, affect the size, number or fluorescent intensity of GFP-expressing neurons, and affect the mean
lifespan (Table 3).
Amaranthus caudatus agglutinin (ACA)-TRITC co-localized with DAergic neurons at the highest
dose group (0.32 µM). As shown in the graph, when the green color from GFP fused DAergic neurons
(Figure 4a) and the red color from TRITC conjugated ACA (Figure 4b) was overlapped, the co-localized
area showed bright yellow color (Figure 4c), which demonstrated that ACA was successfully transported
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from gut to DAergic neurons in C. elegans organism. ACA did not the affect the number of DAergic
neurons (Figure 4d). ACA did not affect the intensity of DAergic neurons (Figure 4e). Area of DAergic
neurons was decreased by higher doses of ACA (0.096 µM & 0.32 µM, P<0.05, Figure 4f). APS was
decreased dose-dependently (Figure 4g). The mean lifespan was reduced by all doses (0.032 µM, 0.096
µM & 0.32 µM) from 18 days to 14, 10 and 7 days dose-dependently (-22%, -44% & -60%, P<0.05,
Figure 4h).
Table 3. Lectins detected in the neurons by co-localization
Lectins
ACA

PNA

EEA

Dose (µM)
0.032
0.096
0.32
0.018
0.054
0.18
0.048
0.136
0.48

GFP #










GFP intensity










GFP size










Lifespan










 Indicates decreasing trend, P<0.05
 Indicates increasing trend, P<0.05
 Indicates no significant alternation, P>0.05
Arachis hypogaea agglutinin (PNA)-TRITC co-localized with GFP-GAergic neurons after one
week of treatment (0.018 µM, 0.054 µM & 0.18 µM, Figure 5). Number of GFP-DAergic neurons was
increased at the lowest dose (0.018 µM, P<0.05, Figure 5d). The size and intensity of GFP-GAergic
neurons was not altered (Figure 5e & Figure 5f). APS was dose-dependently reduced at all doses (Figure
5g). The mean lifespan was reduced by higher doses (0.054 µM and 0.18 µM) from 19 days to 15 days
and 14 days (-24% and -27%, P<0.05, Figure 5h).
Euonymus europaeus agglutinin (EEA)-TRITC co-localized with DAergic neurons at the lowest
dose groups (0.048 µM, Figure 6). As shown in the graph, when the green color from GFP fused DAergic
neurons (Figure 6a) and the red color from TRITC conjugated ACA (Figure 6b) overlapped, the co45

localized area showed bright yellow color (Figure 6c), which demonstrated that EEA was successfully
transported from gut to DAergic neurons in C. elegans organism.

Figure 4. ACA co-localized with GFP-DAergic neurons in C. elegans at the highest dose (0.32 µM). A)
GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red), C) Co-localization of the GFPDAergic neurons in merged A and B (yellow). D) The number of DAergic neurons was not altered. E)
The intensity of DAergic neurons was not altered. F) The area of DAergic neurons was reduced by two
higher doses (0.096 µM & 0.32 µM, P<0.05). G) APS was reduced dose-dependently. H) The mean
lifespan was reduced by all doses (0.032 µM, 0.096 µM & 0.32 µM) from 18 days to 14, 10 and 7 days (22%, -44% & -60%, P<0.05). * indicates statistical significance.
46

Figure 5. PNA co-localized with GFP-DAergic neurons in C. elegans at all doses (0.018 µM, 0.054 µM
& 0.18 µM). A) GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red), C) Co-localization
of the GFP-DAergic neurons in merged A and B (yellow). D) Number of GFP-DAergic neurons was
increased at the lowest dose (0.018 µM, P<0.05). E) The intensity of GFP-DAergic neurons was not
altered. F) The size of GFP-DAergic neurons was not altered. G) APS was dose-dependently reduced at
all doses. H) The mean lifespan was reduced by higher doses (0.054 µM and 0.18 µM) from 19 days to
15 days and 14 days (-24% and -27%, P<0.05). * indicates statistical significance
The number of DAergic neurons was reduced by the highest dose of EEA (0.48 µM, P<0.05,
Figure 6d). The intensity of DAergic neurons was reduced by the highest dose of EEA (0.48 µM, P<0.05,
Figure 6e). Area of DAergic neurons was increased by highest dose of EEA (0.48 µM, P<0.05, Figure
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6f). APS was decreased dose-dependently (Figure 6g). The mean lifespan was reduced dose-dependently
by all doses (0.048 µM, 0.136 µM & 0.48 µM) from 19 days to 14, 9 and 7 days (-27%, -53% & -62%,
P<0.05, Figure 6h).

Figure 6. EEA co-localized with GFP-DAergic neurons in C. elegans at the lowest dose (0.048 µM). A)
GFP-DAergic neurons (green), B) EEA-TRITC in the neuron (red), C) Co-localization of the GFPDAergic neurons in merged A and B (yellow). D) The number of DAergic neurons was reduced by the
highest dose (0.48 µM, P<0.05). E) The intensity of DAergic neurons was reduced by the highest dose of
EEA (0.48 µM, P<0.05). F) Area of DAergic neurons was increased by highest dose of EEA (0.48 µM,
P<0.05). G) APS was decreased dose-dependently. H) The mean lifespan was reduced dose-dependently
by all doses (0.048 µM, 0.136 µM & 0.48 µM) from 19 days to 14, 9 and 7 days (-27%, -53% & -62%,
P<0.05). * indicates statistical significance.
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1.3.2 Lectins altered the GFP-DAergic neurons without co-localization
Seventeen lectins PHA-E, PSA, UEA I, WGA, LcH, S-WGA, AIA, CSA, DBA, GNA, GSL I, HHA,
PHA-L, SBA, Con A or CPA were not observed to co-localize with GFP-DAergic neurons, but most of
them affected the number, intensity or size of DAergic neurons or the mean lifespan (Table 4).
Table 4. Lectins which alter number, GFP-intensity, or size of DAergic neurons without observed colocalization
Lectins
PHA-E

PSA

UEA I

WGA

LcH

S-WGA

AIA

CSA

DBA

Dose (µM)
0.017
0.054
0.17
0.043
0.129
0.43
0.033
0.099
0.33
0.046
0.138
0.46
0.05
0.15
0.5
0.046
0.138
0.46
0.031
0.093
0.31
0.065
0.195
0.65
0.018
0.054
0.18

GFP #




























GFP intensity




























 Indicates decreasing trend, P<0.05
 Indicates increasing trend, P<0.05
 Indicates no significant alternation, P>0.05
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GFP size




























Lifespan




























Table 4 continued. Lectins which alter number, GFP-intensity, or size of DAergic neurons without
observed co-localization
Lectins
GNA

GSL I

HHA

PHA-L

SBA

Con A

CPA

STA

Dose (µM)
0.077
0.231
0.77
0.018
0.054
0.18
0.04
0.12
0.4
0.017
0.051
0.17
0.017
0.051
0.17
0.019
0.057
0.19
0.047
0.141
0.47
0.02
0.06
0.2

GFP #

























GFP intensity

























GFP size

























Lifespan

























 Indicates decreasing trend, P<0.05
 Indicates increasing trend, P<0.05
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Phaseolus vulgaris (PHA-E)-rhodamine did not show co-localization with but affected DAergic
neurons. The number of GFP-DAergic neurons was not altered (Figure 7a). The fluorescence intensity
of GFP-DAergic neurons was increased dose-dependently at all doses (0.017 µM, 0.054 µM & 0.17 µM,
P<0.05, Figure 7b). The average size of GFP-DAergic neurons was also reduced at the highest dose (0.17
µM, P<0.05, Figure 7c). The APS was increased dose-dependently at lower doses (Figure 7d). The mean
lifespan was increased at a medium dose (0.054 µM) from 17 days to 23 days (39%, P<0.05, Figure 7e).
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Figure 7. PHA-E-rhodamine did not show co-localization with DAergic neurons in liquid culture but
affected the DAergic neurons. A) Number of DAergic neurons was not altered. B) The fluorescence
intensity of GFP-DAergic neurons was increased dose-dependently at all doses (0.017 µM, 0.054 µM &
0.17 µM, P<0.05). C) The average size of GFP-DAergic neurons was also reduced at the highest dose
(0.17 µM, P<0.05). D) The APS was increased dose-dependently at lower doses. E) The mean lifespan
was increased at a medium dose (0.054 µM) from 17 days to 23 days (39%, P<0.05). * indicates statistical
significance.
Pisum Sativum agglutinin (PSA)-rhodamine did not show co-localization with GFP-DAergic
neurons but affected the DAergic neurons. The number of DAergic neurons was not altered (Figure 8a).
The intensity was diminished at the highest dose (0.43 µM, P<0.05, Figure 8b). The size was reduced at
the lowest dose (0.043 µM, P<0.05, Figure 8c). The APS was increased at all doses (Figure 8d). The
mean lifespan was increased at doses (0.043 µM & 0.43 µM) from 22 days to 27 days (22% and 23%,
P<0.05, Figure 8e).
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Figure 8. PSA-rhodamine did not show co-localization with GFP-DAergic neurons but affected the GFPDAergic neurons in C. elegans. A) The number of DAergic neurons was not altered. B) The intensity
was diminished at the highest dose (0.43 µM, P<0.05). C) The size was reduced at the lowest dose (0.043
µM, P<0.05). D) The APS was increased at all doses. E) The mean lifespan was increased at doses (0.043
µM & 0.43 µM) from 22 days to 27 days (22% & 23%, P<0.05). * indicates statistical significance.
Ulex Europaeus I (UEA I)-TRITC did not show co-localization with GFP-DAergic neurons in C.
elegans but affected the DAergic neurons. The number of DAergic neurons was not altered (Figure 9a).
The intensity was diminished at all doses (0.033, 0.099 & 0.33 µM, P<0.05, Figure 9b). The size was
reduced at all doses (0.033, 0.099 & 0.33 µM, P<0.05, Figure 9c). The APS was increased at the low dose
(Figure 9d). The mean lifespan was increased by low dose (0.033 µM) from 22 days to 25 days (13%,
P<0.05, Figure 9e).
Triticum vulgaris agglutinin (WGA)-rhodamine was not detected as transported to but affected
DAergic neurons. The number of DAergic neurons was not altered (Figure 10a). The intensity of the
GFP-DAergic neurons was increased at the highest dose (0.46 µM, P<0.05, Figure 10b). The area of the
DAergic neurons was reduced at all doses (P<0.05, Figure 10c). The APS was increased at all doses
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(Figure 10d). The mean lifespan was increased at the highest dose (0.46 µM) from 20 days to 24 days
(22%, P<0.05, Figure 10e).

Figure 9. UEA I-TRITC did not show co-localization with GFP-DAergic neurons but affected the DAergic
neurons. A) The number of DAergic neurons was not altered. B) The intensity was diminished at all
doses (0.033, 0.099 & 0.33 µM, P<0.05). C) The size was reduced at all doses (0.033, 0.099 & 0.33 µM,
P<0.05). D) The APS was increased at the low dose. E) The mean lifespan was increased by low dose
(0.033 µM) from 22 days to 25 days (13%, P<0.05). * indicates statistical significance.
Lens culinaris (LcH)-TRITC was not detected as transported to but affected DAergic neurons.
The number of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05, Figure
11a). The intensity of the GFP-DAergic neurons was increased at the lowest dose (0.05 µM, P<0.05,
Figure 11b). The area of the DAergic neurons was not altered (Figure 11c). The APS was increased at
the lowest dose and reduced at the highest dose (Figure 10d). The mean lifespan was increased at the
lowest dose (0.05 µM) from 18 days to 23 days (27%, P<0.05), and decreased at the highest dose (0.5 µM)
to 12 days (37%, P<0.05, Figure 11e).
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Figure 10. WGA-rhodamine affected the intensity and area of DAergic neurons. A) The number of
DAergic neurons was not altered. B) The intensity of the GFP-DAergic neurons was increased at the
highest dose (0.46 µM, P<0.05). C) The area of the DAergic neurons was reduced at all doses (P<0.05).
D) The APS was increased at all doses. E) The mean lifespan was increased at the highest dose (0.46 µM)
from 20 days to 24 days (22%, P<0.05). * indicates statistical significance.
Lens culinaris (LcH)-TRITC was not detected as transported to but affected DAergic neurons.
The number of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05, Figure
11a). The intensity of the GFP-DAergic neurons was increased at the lowest dose (0.05 µM, P<0.05,
Figure 11b). The area of the DAergic neurons was not altered (Figure 11c). The APS was increased at
the lowest dose and reduced at the highest dose (Figure 10d). The mean lifespan was increased at the
lowest dose (0.05 µM) from 18 days to 23 days (27%, P<0.05), and decreased at the highest dose (0.5 µM)
to 12 days (37%, P<0.05, Figure 11e).
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Figure 11. LcH-TRITC was not detected as transported to but affected DAergic neurons. A) The number
of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05). B) The intensity
of the GFP-DAergic neurons was increased at the lowest dose (0.05 µM, P<0.05). C) The area of the
DAergic neurons was not altered. D) The APS was increased at the lowest dose and reduced at the highest
dose. E) The mean lifespan was increased at the lowest dose (0.05 µM) from 18 days to 23 days (27%,
P<0.05), and decreased at the highest dose (0.5 µM) to 12 days (37%, P<0.05). * indicates statistical
significance.
Triticum vulgaris (Succinylated) S-WGA-rhodamine did not show co-localization but affected
DAergic neurons in C. elegans. The number of the GFP-DAergic neurons was decreased at lower doses
(0.046 µM & 0.138 µM, P<0.05, Figure 12a). The fluorescent intensity of GFP-DAergic neurons was
increased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05, Figure 12b). The size of GFP-DAergic
neurons was decreased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05, Figure 12c). The APS
was increased at a lower dose, and decreased at a higher dose (Figure 12d). The mean lifespan was
increased at the lowest dose (0.138 µM) from 21 days to 23 days (9%, P<0.05), and decreased at the
highest dose (0.46 µM) to 12 days (-43%, P<0.05, Figure 12e).
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Figure 12. S-WGA-rhodamine affected GFP-DAergic neurons in C. elegans. A) The number of the GFPDAergic neurons was decreased at lower doses (0.046 µM & 0.138 µM, P<0.05). B) The fluorescent
intensity of GFP-DAergic neurons was increased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05).
C) The size of GFP-DAergic neurons was decreased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05).
D) The APS was increased at a low dose, and decreased does-dependently at higher doses. E) The mean
lifespan was increased at the lowest dose (0.138 µM) from 21 days to 23 days (9%, P<0.05), and decreased
at the highest dose (0.46 µM) to 12 days (-43%, P<0.05). * indicates statistical significance.
Artocarpus integrifolia agglutinin (AIA)-TRITC did not show co-localization and did not affect
DAergic neurons in C. elegans. The number of the GFP-DAergic neurons was not altered (Figure 13a).
The fluorescent intensity of GFP-DAergic neurons was not altered by AIA (Figure 13b). The size of GFPDAergic neurons was not altered by AIA (Figure 13c). The APS was decreased at all doses (Figure 13d).
The mean lifespan was decreased at all doses (0.046 µM, 0.138 µM & 0.46 µM) from 24 days to 15 days,
13 days and 11 days (-36%, -47% & -56%, P<0.05, Figure 13e).
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Figure 13. AIA-TRITC did not show co-localization and did not affect DAergic neurons in C. elegans.
A) The number of the GFP-DAergic neurons was not altered. B) The fluorescent intensity of GFPDAergic neurons was not altered. C) The size of GFP-DAergic neurons was not altered. D) The APS
was decreased at all doses. E) The mean lifespan was decreased at all doses (0.046 µM, 0.138 µM & 0.46
µM) from 24 days to 15 days, 13 days and 11 days (-36%, -47% & -56%, P<0.05). * indicates statistical
significance.
Cytisus scoparius agglutinin (CSA)-TRITC did not show co-localization but affected DAergic
neurons in C. elegans. The number of the GFP-DAergic neurons was reduced at the highest dose (0.65
µM, P<0.05, Figure 14a). The fluorescent intensity of GFP-DAergic neurons was not altered at all doses
(Figure 14b). The size of GFP-DAergic neurons was increased at all doses (0.065 µM, 0.195 µM & 0.65
µM, P<0.05, Figure 14c). The APS was decreased at the highest dose (Figure 14d). The mean lifespan
was reduced at the highest dose only (0.65 µM) from 18 days to 14 days (-22%, P<0.05, Figure 14e).
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Figure 14. CSA-TRITC did not show co-localization but affected DAergic neurons in C. elegans. A) The
number of the GFP-DAergic neurons was reduced at the highest dose (0.65 µM, P<0.05). B) The
fluorescent intensity of GFP-DAergic neurons was not altered at all doses. C) The size of GFP-DAergic
neurons was increased at all doses (0.065 µM, 0.195 µM & 0.65 µM, P<0.05). D) The APS was decreased
at the highest dose. E) The mean lifespan was reduced at the highest dose (0.65 µM) from 18 days to 14
days (-22%, P<0.05). * indicates statistical significance.
Dolichos biflorus agglutinin (DBA)-rhodamine did not show co-localization with GFP-DAergic
neurons but affected the size and fluorescent intensity of DAergic neurons in C. elegans. As shown in the
graph, the number of DAergic neurons was not altered (Figure 15a). The fluorescent intensity of GFPDAergic neurons was increased at the lowest dose (0.018 µM, P<0.05, Figure 15b). The size of GFPDAergic neurons was increased in a dose-dependent trend at all doses (0.018 µM, 0.054 µM & 0.18 µM,
P<0.05, Figure 15c). The APS was increased at a lower dose but decreased at higher doses (Figure 15d).
The mean lifespan was reduced at the highest dose only (0.18 µM) from 19 days to 11 days (-43%, P<0.05,
Figure 15e).
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Figure 15. DBA-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The
number of DAergic neurons was not altered. B) The fluorescence intensity of GFP-DAergic neurons was
increased at the lowest dose (0.018 µM, P<0.05). C) The size of GFP-DAergic neurons was increased in
a dose-dependent trend at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05). D) The APS was increased
at lower dose, and decreased at higher doses. E) The mean lifespan was reduced at the highest dose (0.18
µM) from 19 days to 11 days (-43%, P<0.05). * indicates statistical significance.
Galanthus nivalis agglutinin (GNA)-rhodamine did not show co-localization with GFP-DAergic
neurons or affect the DAergic neurons. The number of DAergic neurons was not altered (Figure 16a).
The fluorescence intensity of GFP-DAergic neurons was not altered (Figure 16b). The size of GFPDAergic neurons was not altered (Figure 16c). The APS was reduced at all doses (Figure 16d). The
mean lifespan was reduced at higher doses dose-dependently (0.077 µM & 0.231 µM) from 24 days to
20 days and 19 days (-16% & -23%, P<0.05, Figure 16e).
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Figure 16. Galanthus nivalis agglutinin (GNA)-rhodamine did not show co-localization with GFPDAergic neurons or affect the DAergic neurons. A) The number of DAergic neurons was not altered. B)
The fluorescence intensity of GFP-DAergic neurons was not altered. C) The size of GFP-DAergic neurons
was not altered. D) The APS was reduced at all doses. E) The mean lifespan was reduced at higher doses
(0.077 µM & 0.231 µM) from 24 days to 20 days and 19 days (-16% & -23%, P<0.05). * indicates
statistical significance.
Griffonia Simplicifolia (GSL I)-TRITC did show co-localization but affected the DAergic neurons
in C. elegans. The number of the GFP-DAergic neurons was not altered in any tested doses (Figure 17a).
The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was dosedependently increased at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05, Figure 17b). The size of
GFP-DAergic neurons was not altered (Figure 17c). The APS was dose-dependently decreased at all
doses (Figure 17d). The mean lifespan was decreased at the highest dose (0.18 µM) from 17 days to 10
days (-37%, P<0.05, Figure 17e).
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Figure 17. GSL I-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The
number of the GFP-DAergic neurons was not altered. B) The fluorescence intensity of GFP-dopamine
transporter protein in DAergic neurons was dose-dependently increased at all doses (0.018 µM, 0.054 µM
& 0.18 µM, P<0.05). C) The size of GFP-DAergic neurons was not altered. D) The APS was dosedependently decreased at all doses. E) The mean lifespan was decreased at the highest dose (0.18 µM)
from 17 days to 10 days (-37%, P<0.05). * indicates statistical significance.
Hippeastrum hybrid agglutinin (HHA)-TRITC did show co-localization but affected the DAergic
neurons in C. elegans. The number of the GFP-DAergic neurons was not altered (Figure 18a). The
fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was increased at all doses
(0.04 µM, 0.12 µM & 0.4 µM, P<0.05, Figure 18b). The size of GFP-DAergic neurons was increased at
the lowest dose (0.04 µM, P<0.05, Figure 18c). The APS was dose-dependently decreased at all doses
(Figure 18d). The mean lifespan was decreased at higher doses (0.12 µM & 0.4 µM) from 21 days to 15
days and 11 days (-29% & -47%, P<0.05, Figure 18e).
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Figure 18. HHA-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The
number of the GFP-DAergic neurons was not altered. B) The fluorescence intensity of GFP-dopamine
transporter protein in DAergic neurons was increased at all doses (0.04 µM, 0.12 µM & 0.4 µM, P<0.05).
C) The size of GFP-DAergic neurons was increased at the lowest dose (0.04 µM, P<0.05). D) The APS
was dose-dependently decreased at all doses. E) The mean lifespan was decreased at higher doses (0.12
µM& 0.4 µM) from 21 days to 15 days and 11 days (-29% & -47%, P<0.05). * indicates statistical
significance.
Phaseolus vulgaris agglutinin-L (PHA-L)-TRITC did show co-localization but affected the
DAergic neurons in C. elegans. The number of the GFP-DAergic neurons was not altered (Figure 19a).
The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was reduced at lower
doses (0.017 µM & 0.051 µM, P<0.05, Figure 19b). The size of GFP-DAergic neurons was increased at
all doses (0.017 µM, 0.051 µM & 0.17 µM, P<0.05, Figure 19c). The APS was increased at a low dose
and reduced at higher doses (Figure 19d). The mean lifespan was reduced at the highest dose (0.17 µM)
from 20 days to 13 days (-34%, P<0.05, Figure 19e).
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Figure 19. PHA-L-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A)
The number of the GFP-DAergic neurons was not altered. B) The fluorescence intensity of GFPdopamine transporter protein in DAergic neurons was reduced at lower doses (0.017 µM & 0.051 µM,
P<0.05). C) The size of GFP-DAergic neurons was increased at all doses (0.017 µM, 0.051 µM & 0.17
µM, P<0.05). D) The APS was increased at a low dose and reduced at higher doses. E) The mean lifespan
was reduced at the highest dose (0.17 µM) from 20 days to 13 days (-34%, P<0.05). * indicates statistical
significance.
Soybean agglutinin (SBA)-TRITC did show co-localization but affected the DAergic neurons in
C. elegans. The number of the GFP-DAergic neurons was decreased at the lowest dose (0.017 µM, P<0.05,
Figure 20a). The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was not
altered (Figure 20b). The size of GFP-DAergic neurons was reduced at the lowest dose (0.017 µM, P<0.05,
Figure 20c). The APS was increased at low doses and reduced at a higher dose (Figure 20d). The mean
lifespan was reduced at the highest dose (0.17 µM) from 20 days to 14 days (-31%, P<0.05, Figure 20e).
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Figure 20. Soybean agglutinin (SBA)-TRITC did show co-localization but affected the DAergic neurons
in C. elegans. A) The number of the GFP-DAergic neurons was decreased at the lowest dose (0.017 µM,
P<0.05). B) The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was not
altered. C) The size of GFP-DAergic neurons was reduced at the lowest dose (0.017 µM, P<0.05). D)
The APS was slightly increased at low doses and reduced at a higher dose. E) The mean lifespan was
reduced at the highest dose (0.17 µM) from 20 days to 14 days (-31%, P<0.05). * indicates statistical
significance.
Concanavalin A (Con A)-TRITC did not show co-localization with but affected GFP-DAergic
neurons in C. elegans. The number of DAergic neurons was not altered (Figure 21a). The fluorescence
intensity of GFP-dopamine transporter protein image in DAergic neurons was increased at the highest
dose (0.19 µM, P<0.05, Figure 21b). The size was reduced at medium dose (0.057 µM, P<0.05, Figure
21c). The APS was increased at all doses (Figure 21d). The mean lifespan was not altered by Con A
(Figure 21e).
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Figure 21. Con A-rhodamine affected the GFP-DAergic neurons in C. elegans. A) The number of
DAergic neurons was not altered. B) The fluorescence intensity of GFP-dopamine transporter protein
image in DAergic neurons was increased at the highest dose (0.19 µM, P<0.05). C) The size was reduced
at medium dose (0.057 µM, P<0.05). D) The APS was increased at all doses. E) The mean lifespan was
not altered. * indicates statistical significance.
Cicer arietinum agglutinin (CPA)-TRITC did not show co-localization with but affected GFPDAergic neurons in C. elegans. The number of DAergic neurons was not altered (Figure 21a). The
fluorescence intensity of GFP-dopamine transporter protein image in DAergic neurons was reduced at the
lowest and the highest doses (0.047 µM & 0.47 µM, P<0.05, Figure 22b). The size of GFP-DAergic
neurons was reduced at the doses (0.047 µM & 0.47 µM, P<0.05, Figure 22c). The APS was increased
at all doses (Figure 21d). The mean lifespan was not altered by any tested doses significantly (P>0.05,
Figure 22e).
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Figure 22. CPA-TRITC did not show co-localization with but affected GFP-DAergic neurons in C.
elegans. A) The number of DAergic neurons was not altered. B) The fluorescence intensity of GFPdopamine transporter protein image in DAergic neurons was reduced at the doses (0.047 µM & 0.47 µM,
P<0.05). C) The size was reduced at the doses (0.047 µM & 0.47 µM, P<0.05). D) The APS was increased
at all doses. E) The mean lifespan was not altered. * indicates statistical significance.
Solanum tuberosum agglutinin (STA)-TRITC did not show co-localization with but affected GFPDAergic neurons in C. elegans. The number of DAergic neurons was not altered in all tested doses (Figure
23a). The fluorescence intensity of GFP-dopamine transporter protein image in DAergic neurons was not
altered (Figure 23). The size was reduced at all doses (0.02 µM, 0.06 µM & 0.2 µM, P<0.05, Figure 23c).
The APS was slightly increased at all doses (Figure 23d). The mean lifespan was not altered in all tested
doses significantly (P<0.05, Figure 23e).
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Figure 23. STA-TRITC did not show co-localization with but affected GFP-DAergic neurons in C. elegans.
A) The number of DAergic neurons was not altered. B) The fluorescence intensity of GFP-dopamine
transporter protein image in DAergic neurons was not altered. C) The size was reduced at all doses (0.02
µM, 0.06 µM & 0.2 µM, P<0.05). D) The APS was slightly increased. E) The mean lifespan was not
altered. * indicates statistical significance.
1.3.3 Lectins affect mobility of C. elegans
Larvae 1 stage of C.elegans were treated with lectins or MPP+ (0.5 mM) as a positive control. The
blank control was supplemented with OP50 only. Travel distance and velocity were evaluated by
measuring the moving pixels of C. elegans that were displayed in the 20 frames of a video clip. All
evaluated twenty lectins significantly reduced the travel distance and velocity of C. elegans showing
similar effects as the positive control MPP+ compared with the blank control OP50 only (Figure 24, Figure
25).
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Figure 24. Lectins and MPP+ decreased the travel distance of C.elegans compared with the blank control
group. * indicates statistical significance compared with the blank control.

Figure 25. Lectins and MPP+ decreased the travel velocity of C.elegans compared with the blank control
group. * indicates statistical significance compared with the blank control.
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1.4

Discussion
Twenty examined dietary plant lectins conjugated to TRITC or rhodamine were tested in the in

vivo C. elegans (egIs1[Pdat-1::GFP]) model. An elevated GFP-dopamine transporter that is expressed
under control of the dopamine transporter (DAT) gene promoter shows enhanced DAT expression and
trafficking by the promoter, transcription factor, and nuclear receptor [125]. All three lectins ACA, EEA
and PNA that co-localized with DAergic neurons decreased the mean lifespan significantly in a dosedependent manner.
Carbohydrate-binding protein toxins are known to survive and traverse the gut intact, as an acutely
toxic substance and can induce serious life-threatening illness in humans and animals.

Distance

pathogenicity of botulinum toxin, as well as cholera toxin, impairs the central nervous system [126]. The
present study was aimed at a new, surprising property of lectins based upon the hypothesis that lectins
may be transported directly by gut absorption to local neurons and transported axonally to distal neurons
where they have an anatomical and potentially a physiological pathophysiological effect. Fluorescent
intensity and co-localization of lectins was observed to suggest transport to GFP-DAergic neurons.
Number and area changes of GFP-dopamine receptor fluorescence in DAergic neurons were observed to
be an effect of the lectins. Involvement of other pathways like indirect effects by interaction of lectins
with glial cells that affected DAergic neurons may be possible, as it was reported that in patients with PD
or Parkinsonism had α-SYN deposited not only in DAergic neurons but also in different kinds of glial
cells [127-129]. Lectins have been used for histochemistry and neuronal tracing only, but were not
previously associated with neuronal toxicity [51, 130, 131].
1.4.1 The occurrence and intensity of individual fluorescently labeled lectins in GFP-DAergic
neurons detected by co-localization
Three lectins (ACA, EEA or PNA) appeared to co-localize with a subgroup of GFP-DAergic
neurons while other lectins had effects on GFP-DAergic neurons where co-localization was not observed.
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Because some effects were seen in neurons where lectins were not detected, this may be due to
undetectable amount of transported lectin, or some unexplained indirect effect. Thus, the number and
GFP-dopamine transporter image of neurons were also evaluated, even when the fed lectin was not
detected. The lack of observation of fluorescence in the neurons using other fed lectins (which, however,
seemed to affect these neurons) may be due to a variety of characteristics. For instance, a critical window
for the lectin to be detectable may have been missed, the lectin may have been partially degraded, losing
the fluorophore, but still retaining neuron-effective activity, or, more likely, undetectable levels of the
lectin have activities in the cytoplasm or nucleus. Future studies with ELISA, other immunocytochemical
studies or radiolabeling may confirm the transport of small amounts of these specific lectins where an
effect is observed without fluorescence co-localization being observed. In addition to the DAergic
neurons, lectins were found mainly contained in the intestine of C. elegans. Few amount of lectins were
also found scattered in the whole body of the animals under the fluorescent microscopy. Observation of
lectins in the whole body may suggest that lectins have access to other organs in C. elegans. ACA was
first isolated from the seeds of Amaranthus caudatus in 1989 [132], and it has been mainly used to describe
the recognition and migration of cell surface receptors of cancer cells [133] [134]. EEA was mainly
known to bind to blood group-related carbohydrates (mainly B and H determinants) and as a new category
of lectins [135]. Structural analysis of EEA indicated that EEA had a β-trefoil fold similar to ricin B-like
(R-type) lectins [136], which is known for its neurotoxicity. PNA was reported to facilitate to isolate
PNA-binding glycoprotein in central nervous system in humans [137], which implied that further
interactions between PNA and these proteins was possible.
1.4.2 Lectin-caused differences in the number of GFP-DAergic neurons
Four lectins (CSA, EEA, SBA and S-WGA) reduced the number of DAergic neurons, it seemed
that these effects were related to the dose used. For CSA and EEA, only the highest dose reduced the
number of DAergic neurons. For SBA and S-WGA, only low doses reduced the number. In contrast to
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EEA, low doses of S-WGA reduced the number of DAergic neurons while the highest dose did not. CSA
and SBA reduced the number of DAergic neurons. The reduction of neuron numbers indicated the toxicity
of these lectins, which was consistent with lifespan results, that both EEA and S-WGA reduced the mean
lifespan significantly. The lectin LcH increased the number of DAergic neurons at both the lowest dose
and the highest dose.
1.4.3 Lectin feeding effects on the fluorescent intensity of GFP-DAergic neurons
Four lectins (CPA, EEA, PHA-L, PSA or UEA I) reduced GFP-dopamine transporter fluorescence
in D-Aergic neurons suggesting damage to DAT, while Con A, CSA, DBA, GSL I, HHA, LcH, PHA-E,
S-WGA or WGA induced an increase indicating a promotion of DAT in the DAergic neurons. PSA, in
some studies, has been shown to be essentially nontoxic in mice both in vivo and in vitro [138]. However,
toxicity measurements in these studies may not include more subtle long term effects of neuronal damage.
Although WGA did not affect the number of GFP-DAergic neurons in the present study, and in other
laboratories, in the in vivo rat gut lumen, reduced expression of heat shock proteins resulting in lowered
protection and greater permeability of epithelial cells. WGA also increases thrombin in human platelets,
and escalates adipogenesis in mesenchymal cells of the mouse limb bud in vitro [50, 139-141], by
unknown mechanisms.
1.4.4 Sizes of GFP-DAergic neurons
ACA, CPA, Con A, PHA-E, PSA, SBA, S-WGA, STA UEA I or WGA significantly reduced the
size of GFP-DAergic neurons. Whether these effects are due to damage to the neurons is not known.
Increased neuron size of a subgroup of GFP-DAergic neurons, however, was also observed with DBA,
EEA, HHA or PHA-L which may have promoted DAT expression, however, whether decrease or increase
in the apparent size of neurons has a physiological effect, or indicates lectin-mediated damage is not yet
known. Toxicity of some lectins and newly discovered side effects of ingestion of PHA and WGA lectins
in human and animals have been observed, mitigated by sucrose feeding [141-143]. In addition, the size
71

of the GFP-DAergic neurons was significantly reduced suggesting a possible toxic effect of cytoplasmic
PHA-E. This observation is in agreement with other studies showing that PHA can damage intestinal
epithelial cells [53, 142], which was prevented or reversed by a PHA-E SIS sucrose [142]. Interestingly,
PHA-E did not show significant change in the number and size of GFP-neurons in C. elegans but
demonstrated enhanced expression of GFP-dopamine transporter fluorescence intensity.

Con A

strengthens extracellular matrixes by promoting production of proteoglycan in mouse chondrocytes in
vitro [140]. In our study, Con A altered GFP-DAergic neurons by reducing the area of GFP-dopamine
transporter fluorescence.
Some specific beneficial activities of a variety of lectins have been reported [140, 144]. In our
studies, DBA was observed in the GFP-DAergic neurons which had the effect of increasing the observed
area of the GFP-labelled DA transporter. This increase may suggest enhanced DAT expression and
trafficking, where GFP is expressed under the dopamine transporter (DAT) promoter [125, 145]. A major
adverse effect of DBA lectin has not been reported elsewhere. In fact, DBA significantly facilitates
cartilagenesis and osteogenesis in mouse limb bud mesenchymal cells in vitro [140].
1.4.5 Elevated fluorescent intensity and size of DAergic neurons
These alterations may reflect a relationship with the insulin receptor and DAT. Glucose provides
a vital energy source for brain and clearly modulates neuronal function [146, 147]. In C. elegans,
hyperglycemia reduces APS, related to human diabetes. These relationships in our study, however, may
represent some signaling interaction of glycemia/insulinemia and DAT. As with other catecholamine
neurotransmitters, inhibitory neurotransmitters are inversely proportional to glycemia, and DA kinetics is
sensitive to hypoglycemia in a complex manner [148]. In rodents, insulin receptors and DAT are densely
present in substantia nigra, insulin may increase DAT mRNA expression, and glycemic index is inversely
associated with the risk of PD [149, 150].
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1.4.6 Lectins affect the lifespan of C. elegans
Lectins can be categorized into four groups based on their effects on the mean lifespan of C.
elegans. 1) Lectins PHA-E, PSA, UEA I or WGA increased the mean lifespan. 2) Lectins ACA, AIA,
CSA, DBA, EEA, GNA, GSL I, HHA, PHA-L, PNA or SBA reduced the mean lifespan. 3) Lectins LcH
or S-WGA showed dual effects in affecting the mean lifespan, with low dose increasing and high dose
decreasing it. 4) Lectins Con A, CPA or STA did not alter the mean lifespan significantly.
1.4.7 Lectins affect the mobility of C. elegans
PD includes four cardinal features, tremor, rigidity, bradykinesia (slowness of movement) and
postural instability, with bradykinesia as the most characteristic and easily recognizable symptom [151].
In addition, among the four symptoms, bradykinesia correlates best with the degree of dopamine
deficiency, rigidity and postural instability correlates less and tremor does not show any correlation [152].
In this study, two important surrogate markers of movement, distance and velocity were evaluated in C.
elegans. C. elegans is a practical and affordable animal model to study symptoms of neurodegenerative
diseases, as they respond to a wide range of stimuli and exhibit characteristic movement patterns [153].
MPP+ has been widely used in various animal models to induce symptom of PD, which can be
selectively taken up by DAergic neurons via DAT[99]. MPP+ (0.5 mM) has been used to induce motor
symptoms that mimic PD’s in C. elegans, which cause apparent mobility reduction after 48 hours of
treatment [96, 97, 154]. Present study showed that all twenty lectins evaluated reduced travel distance
and velocity (P<0.05), mimicking bradykinesia in humans, as the positive control MPP+ (0.5 mM) in C.
elegans organism. The decrease of the distance and velocity of animals implies that motor neurons were
affected, which might be due to neurodegeneration caused by lectins. This observed reduction in the travel
distance and velocity was consistent with the reduction of the number, area or intensity of DAergic
neurons for most tested lectins. Some lectins like PNA, LcH, AIA, DBA, GNA, GSL I or HAA, were not
observed to have any detrimental effects on DAergic neurons in C. elegans in this study, but still caused
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PD like symptoms of slow movement in C. elegans. This phenomenon might indicate that lectins might
have other mechanisms in inducing the PD besides affecting DAergic neurons. α-SYN deposit in both
DAergic neurons and glial cells, lectins might also affect the glial cells in addition to directly or indirectly
participate in the development of the PD [128]. The detailed mechanism of bradykinesia remains
unknown, but a disruption in normal motor cortex activity caused by reduced DAergic function might be
the main cause of bradykinesia [151]. Functional imaging studies suggest that bradykinesia correlates
with impairment in the recruitment of cortical and subcortical systems that regulate kinematic parameters
of movement like velocity [155]. Anatomically, bradykinesia and tremor scores significantly correlate
with cerebral metabolic rate of glucose inversely in bilateral putamen, the metabolic rate of glucose is
higher when the bradykinesia is worse [156], which leads to reduction in the muscle force produced at the
initiation of movement [151]. In a human study, patients with PD were asked to make ballistic elbow
flexion movements, electromyographic signals were recorded and showed that patients with bradykinesia
are unable to energize the appropriate muscles to perform long time movements compared with the control
[157]. Taken together, the results of current study might lend some support to the hypothesis of reduced
DAergic function caused bradykinesia, and the reduced DAergic neuron number, area or intensity caused
by lectins correlate with the reduced mobility in C. elegans to some extent.
Neurotoxins like botulinum toxin or ricin bind to specific receptors on cell membrane, to be
internalized, and exert toxic effects [158, 159]. Similarly, lectins bind to carbohydrate ligands of targeted
cells to be functional, producing effects. Specific sugars may competitively bind and inhibit lectins uptake
[160]. Structurally similar lectins might share similar binding receptors and compete for each other’s
binding sites. The complex GI environment including nutrients and cellular environment might alter the
absorption of certain lectins and their potential biological consequences [161].
In a recent Danish report, patients who had vagal nerves removed 20 years earlier had 40% lower
incidence of PD than control populations. If dietary proteins were one potential etiology for PD, by
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transport to neurons from the gut, as hypothesized here, removal of the vagal nerve would have prevented
or reduced this etiology pathway. Symptoms of motor impairment are typical in PD patients, and
dysfunction of aspects of the autonomic nervous system are often underrated, such as GI motility [162],
rapid eye movement [163], etc. The current study indicates potential transport of some dietary plant
lectins from the GI tract to the DAergic neurons in C. elegans, with direct or indirect effects on these
neurons and diverse effects on APS. This observation may be related to the Braak and Hawkes’
hypothesized unknown etiologic agent for PD or related, for example, to damaged DAergic neurons those
have been found in PD [89, 93]. If related, the process may be gradual, may be additive, related to the
frequency of consumption of certain lectins, and may be determined by the association of lectins with
other factors. Certainly, there is potential for inputs from individual genetic susceptibility, varying sugar
structures profiles in different cell membranes, the receptivity to endocytosis, a disorder or leakage of the
GI lining, and dietary content. Our observations are a tantalizing possible explanation for why dietary
plants have been linked to a risk of developing PD.
1.5
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CHAPTER III. SPECIFIC INHIBITING SUGARS AFFECT THE EFFECTS OF LECTINS ON
LIFESPAN AND DOPAMINERGIC NEURONS IN C. ELEGANS
1.1

Disclaimer
There were anticipated problems with feeding high amounts of sugars to C. elegans as inhibitors of

lectin binding. For example, D-galactosamine perfusion in the liver of rats led to D-galactosamine
accumulate as sugar nucleotides, and reduced the level of uridine diphosphate (UDP), which was needed
for RNA synthesis [1]. Other problems can arise, for example, feeding xylose to rats and mice cause
cataracts due to protein cross linking by "non enzymatic glycosylation" [2, 3]. Sucrose has effects on the
levels of dopamine and opioid mRNA in rat brain similar to the effects of opiate [4]. Other sugars may
cause similar side effects because they spend considerably more time in the open chain aldehyde or ketone
form than glucose, which is the evolutionarily chosen circulating sugar in animals for that reason.
However, we conducted some experiments with simple sugars as inhibitors, which experiments and results
are described here.
1.2

Materials and methods
C. elegans egIs1[Pdat-1::GFP] that express GFP in the 8 DAergic neurons [5, 6] and the standard

food Escherichia coli (E. coli) were obtained from C. elegans Genetics Center (CGC, MN). The C.
elegans model does not require regulation of the Institutional Animal Care and Use Committee.
1.2.1 Culture Escherichia coli (E. coli, OP50)
OP50 were cultured by the standard method described elsewhere [7]. Briefly, approximately 10 µL
of stock E. coli solution was added to media and incubated at 37°C for 24h. The OP50 were then plated
in PetrifilmTM (3M Corporate, St. Paul, MN) at 37°C for 24h until densities of 5×108 to 5×1011 colony
forming units (cfu/ml) were reached and then were fed to the C. elegans ad libitum [7, 8]. The OP50 stock
feeding solution was enriched to 2×109cfu/ml by centrifuging at 2,200 g for 10 minutes and washed with
S-complete buffer twice.
88

1.2.2 C. elegans culture
Mature gravid transgenic C. elegans egIs1[Pdat-1::GFP] were treated with NaOH (1M) and sodium
hypochlorite solution (5.25%, 5:2 ratio) to dissolve the body and release viable eggs [7]. The eggs were
hatched overnight fed ad libitum with LB broth (200 µL/well) containing OP50 5x108 – 5x1011 cfu/ml [9],
after washing with S-complete solution 3 times. The age-synchronized C. elegans were diluted to 100
animals/ml, plated in liquid culture in a 96 well plate (120μl/well, 10-15 animals) [10]. The plate was
tape sealed, bagged, and covered with aluminum foil. All animals were kept in a 20C low temperature
incubator (Revco Tech., Nashville, NC, USA) throughout the experiments. Thirty microliters of 5-Fluoro2′-deoxyuridine (FUDR, 0.6 mM) stock solution was added to each well at larvae 4 stage.
All treatments were applied at day 3 after hatching. Four dose responses of twenty lectins were
obtained for each culture condition in a dark room. Control animals were fed with OP50. Experimental
groups were fed rhodamine/TRITC-conjugated lectins with or without additional SIS(s). The SIS, or
lectin plus SIS were incorporated into feeding medium with OP50. Each group of nematodes were
collected and fixed after the first week for the liquid culture as described elsewhere [11]. Briefly, after
being collected from wells, animals were washed with S-Basal twice, fixed with paraformaldehyde (4%)
over 2h at 4°C and washed with PBS for 5min x 3. Ten microliters of Fluoromount-G (Southern
Biotechnology Associates, Birmingham, AL) was applied to a glass slide followed by 10 µL of the
medium containing C. elegans. At last, a cover glass was mounted on the glass slide.
1.2.3 Select lectins and specific inhibiting sugars (SIS)
Commercially available plant lectins conjugated with TRITC or rhodamine were purchased from
EY labs (San Mateo, USA), Vector Labs (Burlingame, USA), or Sigma-Aldrich (St. Louis, USA). Each
lectin-SIS-inhibition experiment had a SIS-only control group. The dose of SIS for each fluorescenceconjugated lectin was determined by searching histology literature or product manuals. Doses of lectins
and their SISs were used comparable to published work in histochemistry or neuronal tracing [12-14].
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1.2.4 Average probability of survival (APS) assay
All average probability of survival (APS) assays were conducted in liquid culture (96-well plate).
The animals were synchronized and seeded into each well of a plate (n=10-15) and OP50 was added to
each well. Thirty microliters (0.6mM) of fluorodeoxyuridine (FUDR) was added to each well to sterilize
the animals. Four different treatments (50 µL/treatment, n=6 row) including control, SIS only, or lectin
plus SIS were added. The plate was then covered with aluminum foil. The whole procedure was
performed in a dark room to prevent bleaching of fluorophores. After the plate was shaken for 3 minutes,
the survival animals were counted every other day until all were dead under an inverted microscope (Nikon,
Eclipse Ti –S, Japan) at 4x or 10x magnification. Animals were exposed to strong lights to stimulate the
movements [15] and the movement of pharynx was checked to confirm whether the animals were dead
when they were not moving.
1.2.5 Fluorescent microscopy
The GFP-DAergic neurons were identified by FTIC filter (480Ex/520Em) and the number of GFPDAergic neurons counted. Fluorescent intensity of GFP-DAergic neurons and their average sizes (µm2)
were determined by NIS-Elements Advanced Research (version 3.22.11) and compared among the
following groups: control, SISs, and lectins plus SIS. Fluorescent intensity of rhodamine-lectins was
determined by a TRITC filter (580Ex/620Em) to assess co-localization. The magnitude of the effect(s) of
the lectin on the DAergic neurons, the number, fluorescent intensity (arbitrary unit), and sizes (µm2) of
GFP-DAergic neurons were determined and compared among each group. Co-localization was initially
identified with an inverted microscopy (Nikon, Eclipse Ti –S, Japan) and then confirmed at a Z-axle with
laser scanning microscopy (Leica, TCS SP5, Germany).
1.2.6 Solutions and chemicals
Standard NGM agar plates (g): NaCl 3.0g, Bacto-agar (Becton, MD) 20g, Bacto-peptone 2.5g
(Becton, MN), Cholesterol solution 0.1% (0.005/ml 95% ethanol), and dH2O 975ml were mixed.
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Additions to the autoclaved solution (M): CaCl2 1.0 1ml, MgSO4 1.0 1ml, KPO4 pH6 1.0 25ml. LB Broth:
25.0g, dH2O 1L (autoclave). S-basal solution (M): NaCl 0.1, KPO4 pH6 0.05, Cholesterol 0.1%, was
autoclaved. PBS (mM): 115 NaCl, 75 Na2HPO4•7H2O, and 7.5 KH2PO4, pH 7.4.
1.2.7 Statistical analyses
All results are presented as mean ±S.E.M. Analyses were carried out using SAS/STAT® software,
Version 9.4 of the SAS System for Windows (Cary, NC, USA). Survival curves were displayed by
binomial probabilities obtained from logistic regression models as surrogates for survival probabilities
and mean lifespan was estimated via Kaplan-Meier (log-rank). ANOVA models were used to analyze
neuron data. For each group, 10-15 animals were analyzed for liquid culture. An alpha level of 0.5 was
considered statistically significant.
1.3

Results
Diets supplemented with varying concentrations of TRITC-conjugated lectins and their SIS in liquid

culture were fed to C. elegans (Error! Reference source not found.). We observed that some SIS had
the following effects: a) enhancing the effects of lectins on the DAergic neurons or mean lifespan, b)
mitigating the effects of lectins on the DAergic neurons or mean lifespan, or c) reversing the effects of
lectins on the DAergic neurons or mean lifespan.
Amaranthus caudatus agglutinin (ACA)-TRITC co-localized with DAergic neurons at the highest
dose (0.32 µM), with or without the SIS GalNAc. As shown in the graph, when the green color from GFP
fused DAergic neurons (Figure 26a) and the red color from TRITC conjugated ACA (Figure 26b) was
overlapped, the co-localized area showed bright yellow color (Figure 26c), which demonstrated that ACA
was successfully transported from gut to DAergic neurons in C. elegans organism. ACA did not the affect
the number of DAergic neurons (Figure 26d), the intensity of DAergic neurons was reduced by the highest
dose of ACA with the presence of the SIS (0.32 µM, P<0.05, Figure 26e).
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Table 5. Effects of lectins combined with specific inhibiting sugars on lifespan and DAergic neurons in
C. elegans
Lectins
ACA

EEA

PNA

PHA-E

PSA

UEA I

WGA

LcH

S-WGA

AIA

CSA

Dose (µM)
0.032
0.096
0.32
0.048
0.136
0.48
0.018
0.054
0.18
0.017
0.054
0.17
0.043
0.129
0.43
0.033
0.099
0.33
0.046
0.138
0.46
0.05
0.15
0.5
0.046
0.138
0.46
0.031
0.093
0.31
0.065
0.195
0.65

GFP #


































GFP intensity


































 Indicates decreasing trend, P<0.05
 Indicates increasing trend, P<0.05
 Indicates no significant alternation, P>0.05
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GFP size


































Lifespan


































Table 5 continued. Effects of lectins combined with specific inhibiting sugars on lifespan and DAergic
neurons in C. elegans
Lectins
DBA

GNA

GSL I

HHA

PHA-L

SBA

Con A

CPA

STA

Dose (µM)
0.018
0.054
0.18
0.077
0.231
0.77
0.018
0.054
0.18
0.04
0.12
0.4
0.017
0.051
0.17
0.017
0.051
0.17
0.019
0.057
0.19
0.047
0.141
0.47
0.02
0.06
0.2

GFP #




























GFP intensity




























 Indicates decreasing trend, P<0.05
 Indicates increasing trend, P<0.05
 Indicates no significant alternation, P>0.05
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GFP size




























Lifespan




























Figure 26. ACA co-localized with GFP-DAergic neurons in C. elegans at the highest dose (0.32 µM). A)
GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red), C) Co-localization of the GFPDAergic neurons in merged A and B (yellow). D) The number of DAergic neurons was not altered. E)
The intensity of DAergic neurons was decreased by the highest dose (0.32 µM) plus the presence of the
SIS (GalNAc 1.58 mM). F) The area of DAergic neurons was reduced by two higher doses (0.096 µM &
0.32 µM, P<0.05) and the highest dose (0.32 µM, P<0.05) when the SIS was present. G) The APS was
reduced with or without the SIS. H) The mean lifespan was reduced by all doses (0.032 µM, 0.096 µM
& 0.32 µM) from 18 days to 14, 10 and 7 days (-22%, -44% & -60%, P<0.05), or by the SIS only from
18 days to 12 days (-30%, P<0.05). With the presence of the SIS, the mean lifespan was reduced by higher
doses (0.096 µM & 0.32 µM) from 12 days to 8 days and 7 days (-32% & -43%, P<0.05). * indicates
statistical significance, # indicates SIS plus OP50 vs. OP50 only.
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Area of DAergic neurons was decreased by higher doses of ACA (0.096 µM & 0.32 µM, P<0.05),
and decreased by the highest dose of ACA plus GalNAc (0.32 µM, P<0.05, Figure 26f). APS was
decreased dose-dependently with or without the presence of the SIS (Figure 26g). The mean lifespan was
reduced by all doses (0.032 µM, 0.096 µM & 0.32 µM) from 18 days to 14, 10 and 7 days (-22%, -44%
& -60%, P<0.05), or by the SIS only from 18 days to 12 days (-30%, P<0.05). With the presence of the
SIS, the mean lifespan was reduced by higher doses (0.096 µM & 0.32 µM) from 12 days to 8 days and 7
days (-32% & -43%, P<0.05, Figure 26h).
Euonymus europaeus agglutinin (EEA)-TRITC co-localized with DAergic neurons at the lowest
dose (0.048 µM), with or without the SIS lactose. As shown in the graph, when the green color from GFP
fused DAergic neurons (Figure 27a) and the red color from TRITC conjugated EEA (Figure 27b) was
overlapped, the co-localized area showed bright yellow color (Figure 27c), which demonstrated that EEA
was successfully transported from gut to DAergic neurons in C. elegans organism. The number of
DAergic neurons was reduced by the highest dose (0.48 µM, P<0.05), which was blocked by the SIS
lactose (10 mM, Figure 27d). The intensity of DAergic neurons was reduced by the highest dose of EEA
(0.48 µM, P<0.05) which was reversed by the SIS at the lowest dose (0.048 µM, P<0.05). The SIS did
not block the effect of the highest dose of EEA in reducing the intensity of DAergic neurons (Figure 27e).
Area of DAergic neurons was increased by highest dose (0.48 µM, P<0.05), the presence of the SIS
reduced the magnitude of this effect. Medium dose of EEA plus the SIS reduced the size of DAergic
neurons (0.136 µM, P<0.05, Figure 27f). APS was decreased dose-dependently with or without the SIS
(Figure 27g). The mean lifespan was reduced dose-dependently by all doses (0.048 µM, 0.136 µM &
0.48 µM) from 19 days to 14, 9 and 7 days (-27%, -53% & -62%, P<0.05), or by the SIS only from 19
days to 11 days (-43%, P<0.05). With the presence of the SIS, the mean lifespan was reduced by higher
doses (0.136 µM & 0.48 µM) from 11 days to 7 days and 7 days (-32% & -35%, P<0.05, Figure 27h).
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Figure 27. EEA co-localized with GFP-DAergic neurons in C. elegans at the lowest dose (0.048 µM). A)
GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red), C) Co-localization of the GFPDAergic neurons in merged A and B (yellow). D) The number of DAergic neurons was reduced by the
highest dose (0.48 µM, P<0.05), which was blocked by the SIS lactose 10 mM. E) The intensity of
DAergic neurons was reduced by the highest dose of EEA (0.48 µM, P<0.05) which was reversed by the
SIS at the lowest dose (0.048 µM, P<0.05). F) Area of DAergic neurons was increased by highest dose
of EEA (0.48 µM, P<0.05), the presence of the SIS reduced the magnitude of this effect. Middle dose of
EEA plus the SIS reduced the size of DAergic neurons (0.136 µM, P<0.05). G) APS was decreased dosedependently with or without the presence of the SIS. H) The mean lifespan was reduced dose-dependently
by all doses (0.048 µM, 0.136 µM & 0.48 µM) from 19 days to 14, 9 and 7 days (-27%, -53% & -62%,
P<0.05), or by the SIS only from 19 days to 11 days (-43%, P<0.05). With the presence of the SIS, the
mean lifespan was reduced by higher doses (0.136 µM & 0.48 µM) from 11 days to 7 days and 7 days (32% & -35%, P<0.05). * indicates statistical significance, # indicates SIS plus OP50 vs. OP50 only.
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Arachis hypogaea agglutinin (PNA)-TRITC co-localized with GFP-GAergic neurons after one
week of treatment (0.018 µM, 0.054 µM & 0.18 µM). As shown in the graph, when the green color from
GFP fused DAergic neurons (Figure 28a) and the red color from TRITC conjugated EEA (Figure 28b)
was overlapped, the co-localized area showed bright yellow color (Figure 28c), which demonstrated that
PNA was successfully transported from gut to DAergic neurons in C. elegans organism. Number of GFPDAergic neurons was increased at the lowest dose (0.018 µM, P<0.05), which was blocked by the SIS
galactose 200 mM (Figure 28d). The size and intensity of GFP-GAergic neurons was not altered (Figure
28e & Figure 28f). SIS galactose (200 mM) treatment decreased the size of GFP-DAergic neurons (0.054
µM & 0.18 µM, P<0.05) without altering the number and intensity. APS was dose-dependently reduced
at all doses, reversed by SIS, and was reduced by SIS galactose (200 mM) only (Figure 28g). The mean
lifespan was reduced by higher doses (0.054 µM and 0.18 µM) from 19 days to 15 days and 14 days (24% and -27%, P<0.05), which was reversed in presence of SIS galactose with an increase at the highest
dose (0.18 µM) from 12 days to 16 days (33%, P<0.05). The mean lifespan was reduced by SIS only from
19 days to 12 days (-36%, P<0.05, Figure 28h).
Phaseolus vulgaris (PHA-E)-rhodamine did not show co-localization with DAergic neurons in
liquid culture but affected the DAergic neurons. The number of GFP-DAergic neurons was not altered,
but reduced at the highest dose with the SIS present (0.17 µM, P<0.05, Figure 29a). The fluorescence
intensity of GFP-DAergic neurons was increased dose-dependently at all doses (0.017 µM, 0.054 µM &
0.17 µM, P<0.05), which was blocked by the SIS at the highest dose (0.17 µM, Figure 29b). The average
size of GFP-DAergic neurons was also reduced at the highest dose (0.17 µM, P<0.05), which was
augmented by the presence of the SIS (Figure 29c). The APS was increased dose-dependently at lower
doses, which was blocked by SIS GalNAc (1.58 mM), and was reduced by GalNAc only (Figure 29d),
possibly due to Uridine diphosphate (UDP) depletion [1].
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Figure 28. PNA co-localized with GFP-DAergic neurons in C. elegans at all doses (0.018 µM, 0.054 µM
& 0.18 µM). A) GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red), C) Co-localization
of the GFP-DAergic neurons in merged A and B (yellow). D) Number of GFP-DAergic neurons was
increased at the lowest dose (0.018 µM, P<0.05), which was blocked by the SIS galactose 200 mM. E)
The intensity of GFP-DAergic neurons was not altered. F) The size of GFP-DAergic neurons was not
altered, but was reduced with the presence of the SIS at higher doses (0.054 µM & 0.18 µM, P<0.05). G)
APS was dose-dependently reduced at all doses, reversed by SIS, and was reduced by SIS galactose (200
mM) only. H) The mean lifespan was reduced by higher doses (0.054 µM and 0.18 µM) from 19 days to
15 days and 14 days (-24% and -27%, P<0.05), which was reversed in presence of SIS galactose with an
increase at the highest dose (0.18 µM) from 12 days to 16 days (33%, P<0.05). The mean lifespan was
reduced by SIS galactose (200 mM) only from 19 days to 12 days (-36%, P<0.05). * indicates statistical
significance, # indicates SIS plus OP50 vs. OP50 only.
98

The mean lifespan was increased at a middle dose of PHA-E (0.054 µM) from 17 days to 23
days (39%, P<0.05), which was blocked by GalNAc, and was reduced at a higher dose (0.17 µM) from
11 days to 8 days (-28%, P<0.05) in presence of SIS. GalNAc (1.58 mM) only reduced the mean
lifespan from 17 days to 11 days (-34%, P<0.05, Figure 29e).

Figure 29. PHA-E-rhodamine did not show co-localization with DAergic neurons in liquid culture but
affected the DAergic neurons. A) Number of DAergic neurons was reduced at the highest dose (0.17
µM) with the SIS present. B) The fluorescence intensity of GFP-DAergic neurons was increased dosedependently at all doses (0.017 µM, 0.054 µM & 0.17 µM, P<0.05), which was blocked by the SIS at
the highest dose (0.17 µM). C) The average size of GFP-DAergic neurons was also reduced at the
highest dose (0.17 µM, P<0.05), which was augmented by the presence of the SIS. D) The APS was
increased dose-dependently at lower doses, which was blocked by SIS GalNAc (1.58 mM), and was
reduced by GalNAc only. E) The mean lifespan was increased at a middle dose (0.054 µM) from 17
days to 23 days (39%, P<0.05), which was blocked by GalNAc, and was reduced at a higher dose (0.17
µM) from 11 days to 8 days (-28%, P<0.05) in presence of SIS. GalNAc (1.58 mM) only reduced the
mean lifespan from 17 days to 11 days (-34%, P<0.05). * indicates statistical significance, # indicates
SIS plus OP50 vs. OP50 only.
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Pisum Sativum agglutinin (PSA)-rhodamine did not show co-localization with GFP-DAergic
neurons but affected the DAergic neurons. The number of DAergic neurons was not altered, but was
reduced at the highest dose (0.43 µM, P<0.05) in presence of the SIS α-methylmannoside (200 mM) plus
α-methylglucoside (200 mM, Figure 30a). The intensity was diminished at the highest dose of PSA (0.43
µM, P<0.05), which was eliminated in presence of the SIS (Figure 30b).

Figure 30. PSA-rhodamine did not show co-localization with GFP-DAergic neurons but affected the GFPDAergic neurons in C. elegans. A) The number of DAergic neurons was not altered, but was reduced at
the highest dose (0.43 µM, P<0.05) in presence of the SIS α-methylmannoside (200 mM) plus αmethylglucoside (200 mM). B) The intensity was diminished at the highest dose (0.43 µM, P<0.05),
which was eliminated in presence of the SIS. C) The size was reduced at the lowest dose (0.043 µM,
P<0.05), which was blocked by the SIS, and was increased it at middle dose (0.129 µM, P<0.05) with the
SIS. D) The APS was increased at all doses, which was blocked at the highest dose in presence of the SIS.
E) The mean lifespan was increased by lower doses (0.043 µM & 0.43 µM) from 22 days to 27 days (22%
& 23%, P<0.05), which was blocked by SIS at the highest dose (0.43 µM), and was increased at a lower
dose (0.043 µM) from 23 days to 28 days in presence of the SIS (21%, P<0.05). * indicates statistical
significance.
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The size was reduced at the lowest dose (0.043 µM, P<0.05), which was blocked by the SIS, and
was increased it at medium dose (0.129 µM, P<0.05) with the SIS (Figure 30c). The APS was increased
at all doses of PSA, which was blocked at the highest dose in presence of the SIS (Figure 30d). The mean
lifespan was increased by lower doses (0.043 µM & 0.43 µM) from 22 days to 27 days (22% and 23%,
P<0.05), which was blocked by SIS at the highest dose (0.43 µM), and was increased at a lower dose
(0.043 µM) from 23 days to 28 days in presence of the SIS (21%, P<0.05, Figure 30e).
Ulex Europaeus I (UEA I)-TRITC did not show co-localization with GFP-DAergic neurons but
affected the DAergic neurons. The number of DAergic neurons was not altered, but was increased at the
highest dose (0.33 µM, P<0.05) in presence of the SIS L-fucose (50 mM, Figure 31a). The intensity was
diminished at all doses (0.033, 0.099 & 0.33 µM, P<0.05), which was eliminated in presence of the SIS
(Figure 31b). The size was reduced at all doses (0.033, 0.099 & 0.33 µM, P<0.05), which was blocked
by the SIS, and was increased at the highest dose (0.33 µM, P<0.05) in presence of the SIS (Figure 31c).
The APS was increased at the lowest dose, which was blocked by the SIS (Figure 31d). The mean lifespan
was increased by the lowest dose (0.033 µM) from 22 days to 25 days (13%, P<0.05), which was blocked
by SIS, and was reduced at the highest dose (0.99 µM) from 21 days to 16 days in presence of the SIS
(26%, P<0.05, Figure 31e).
Triticum vulgaris agglutinin (WGA)-rhodamine was not detected as being transported to the
DAergic neurons but affected the DAergic neurons. The number of DAergic neurons was not altered
(Figure 32a). The intensity of the GFP-DAergic neurons was increased at the highest dose (0.46 µM,
P<0.05), which was augmented in presence of the SIS (Figure 32b). The area of the DAergic neurons was
reduced at all doses (P<0.05), which was blocked by the SIS (Figure 32c). The APS was increased at all
doses, which was blocked by SIS (Figure 32d). The mean lifespan was increased at the highest dose (0.46
µM) from 20 days to 24 days (22%, P<0.05), which was blocked by the SIS (Figure 32e).
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Figure 31. UEA I-TRITC did not show co-localization with GFP-DAergic neurons but affected the
DAergic neurons. A) The number of DAergic neurons was not altered, but was increased at the highest
dose (0.33 µM, P<0.05) in presence of the SIS L-fucose (50 mM). B) The intensity was diminished at all
doses (0.033, 0.099 & 0.33 µM, P<0.05), which was eliminated in presence of the SIS. C) The size was
reduced at all doses (0.033, 0.099 & 0.33 µM, P<0.05), which was blocked by the SIS, and was increased
at the highest dose (0.33 µM, P<0.05) in presence of the SIS. D) The APS was increased at the low dose,
which was blocked in presence of the SIS. E) The mean lifespan was increased by low dose (0.033 µM)
from 22 days to 25 days (13%, P<0.05), which was blocked by SIS, and was reduced at the highest dose
(0.99 µM) from 21 days to 16 days in presence of the SIS (26%, P<0.05). * indicates statistical
significance.
Lens culinaris (LcH)-TRITC was not detected as transported to but affected DAergic neurons.
The number of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05), which
was blocked at low dose and reversed at high does (0.5 µM, P<0.05, Figure 33a). The intensity of the
GFP-DAergic neurons was increased at the lowest dose (0.05 µM, P<0.05), which was reversed in the
presence of the SIS. Besides, the intensity was reduced at higher doses (0.05 µM & 0.15 µM, P<0.05) in
presence of the SIS (Figure 33b). The area of the DAergic neurons was not altered (P>0.05), which was
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reduced by the highest dose (0.5 µM, P<0.05) in presence of the SIS (Figure 33c). The APS was increased
at the lowest dose and reduced at the highest dose, which was enhanced by the SIS (Figure 33d). The
mean lifespan was increased at the lowest dose (0.05 µM) from 18 days to 23 days (27%, P<0.05) which
was blocked by the SIS, and decreased at the highest dose (0.5 µM) to 12 days (-37%, P<0.05) which was
enhanced in presence of the SIS. The mean lifespan was increased by the SIS only from 18 days to 27
days (45%, P<0.05, Figure 33e).

Figure 32. WGA-rhodamine affected the intensity and area of DAergic neurons. A) The number of
DAergic neurons was not altered by WGA with or without the SIS chitin hydrolysate (2.5%). B) The
intensity of the GFP-DAergic neurons was increased at the highest dose (0.46 µM, P<0.05), which was
augmented in the presence of the SIS. C) The area of the DAergic neurons was reduced at all doses
(P<0.05), which was blocked by the SIS. D) The APS was increased at all doses, which was blocked by
the SIS. E) The mean lifespan was increased at the highest dose (0.46 µM) from 20 days to 24 days (22%,
P<0.05), which was blocked by the SIS. * indicates statistical significance.
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Figure 33. LcH-TRITC was not detected as transported to but affected DAergic neurons. A) The number
of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05), which was blocked
at low dose and reversed at high does (0.5 µM, P<0.05). B) The intensity of the GFP-DAergic neurons
was increased at the lowest dose (0.05 µM, P<0.05), which was reversed in the presence of the SIS.
Besides, the intensity was reduced at higher doses (0.05 µM & 0.15 µM, P<0.05) in presence of the SIS.
C) The area of the DAergic neurons was not altered (P>0.05), which was reduced by the highest dose (0.5
µM, P<0.05) in presence of the SIS. D) The APS was increased at the lowest dose and reduced at the
highest dose, which was enhanced by the SIS. E) The mean lifespan was increased at the lowest dose
(0.05 µM) from 18 days to 23 days (27%, P<0.05) which was blocked by the SIS, and decreased at the
highest dose (0.5 µM) to 12 days (37%, P<0.05) which was enhanced in presence of the SIS. The mean
lifespan was increased by the SIS only from 18 days to 27 days (45%, P<0.05). * indicates statistical
significance, # indicates SIS plus OP50 vs. OP50 only.
Triticum vulgaris (Succinylated) S-WGA-rhodamine did not show co-localization but affected
DAergic neurons in C. elegans. The number of the GFP-DAergic neurons was decreased at lower doses
(0.046 µM & 0.138 µM, P<0.05), which was blocked by the SIS chitin hydrolysate (2.5%, Figure 34a).
The fluorescent intensity of GFP-DAergic neurons was increased at all doses (0.046 µM, 0.138 µM &
0.46 µM, P<0.05), which was blocked by the SIS at medium dose (0.138 µM, P>0.05) and reversed by
104

the highest dose (0.46 µM, P<0.05, Figure 34b). The size of GFP-DAergic neurons was decreased at all
doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05), which was blocked by the SIS (Figure 34c).

Figure 34. S-WGA-rhodamine affected GFP-DAergic neurons in C. elegans. A) The number of the GFPDAergic neurons was decreased at lower doses (0.046 µM & 0.138 µM, P<0.05), which was blocked by
the SIS chitin hydrolysate (2.5%). B) The fluorescent intensity of GFP-DAergic neurons was increased
at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05), which was blocked by the SIS at medium dose
(0.138 µM, P>0.05) and reversed by the highest dose (0.46 µM, P<0.05). C) The size of GFP-DAergic
neurons was decreased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05), which was blocked by the
SIS. D) The APS was increased at a low dose, and decreased does-dependently at higher doses, which
was blocked by SIS. E) The mean lifespan was increased at the lowest dose (0.138 µM) from 21 days to
23 days (9%, P<0.05), and decreased at the highest dose (0.46 µM) to 12 days (-43%, P<0.05), which was
blocked by the SIS at all doses. The mean lifespan was reduced by the SIS only from 21 days to 14 days
(-33%, P<0.05). * indicates statistical significance, # indicates SIS plus OP50 vs. OP50 only.
The APS was increased at a low dose, and decreased at higher doses, which was blocked by SIS
(Figure 34d). The mean lifespan was increased at the lowest dose (0.138 µM) from 21 days to 23 days
(9%, P<0.05), and decreased at the highest dose (0.46 µM) to 12 days (-43%, P<0.05), which was blocked
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by the SIS at all doses. The mean lifespan was reduced by the SIS only from 21 days to 14 days (-33%,
P<0.05, Figure 34e).
Artocarpus integrifolia agglutinin (AIA)-TRITC did not show co-localization and did not affect
DAergic neurons in C. elegans. The number of the GFP-DAergic neurons was not altered by AIA, with
or without the SIS galactose (32 mM, P>0.05, Figure 35a).

Figure 35. AIA-TRITC did not show co-localization and did not affect DAergic neurons in C. elegans.
A) The number of the GFP-DAergic neurons was not altered by AIA, with or without the SIS galactose
(32 mM, P>0.05). B) The fluorescent intensity of GFP-DAergic neurons was not altered by AIA (P>0.05).
C) The size of GFP-DAergic neurons was not altered by AIA (P>0.05). D) The APS was decreased at all
doses, which was enhanced by the SIS. E) The mean lifespan was increased at all doses (0.046 µM, 0.138
µM & 0.46 µM) from 24 days to 15 days, 13 days and 11 days (-36%, -47% & -56%, P<0.05), which was
blocked at the lowest dose (0.046 µM) in presence of the SIS. The mean lifespan was reduced by the SIS
only from 24 days to 15 days (-37%, P<0.05). * indicates statistical significance, # indicates SIS plus
OP50 vs. OP50 only.
The fluorescent intensity of GFP-DAergic neurons was not altered by AIA (P>0.05, Figure 35b).
The size of GFP-DAergic neurons was not altered by AIA (P>0.05, Figure 35c). The APS was decreased
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at all doses, which was enhanced by the SIS (Figure 35d). The mean lifespan was increased at all doses
(0.046 µM, 0.138 µM & 0.46 µM) from 24 days to 15 days, 13 days and 11 days (-36%, -47% & -56%,
P<0.05), which was blocked at the lowest dose (0.046 µM) in presence of the SIS. The mean lifespan
was reduced by the SIS only from 24 days to 15 days (-37%, P<0.05, Figure 35e).
Cytisus scoparius agglutinin (CSA)-TRITC did not show co-localization but affected DAergic
neurons in C. elegans. The number of the GFP-DAergic neurons was reduced at the highest dose (0.65
µM, P<0.05), which was blocked by the SIS GalNAc 20 mM (Figure 36a).

Figure 36. CSA-TRITC did not show co-localization but affected DAergic neurons in C. elegans. A) The
number of the GFP-DAergic neurons was reduced at the highest dose (0.65 µM, P<0.05), which was
blocked by the SIS GalNAc 20 mM. B) The fluorescent intensity of GFP-DAergic neurons was not altered
at all doses (P>0.05), which was reduced at high doses (0.195 µM & 0.65 µM, P<0.05) in presence of the
SIS. C) The size of GFP-DAergic neurons was increased at all doses (0.065 µM, 0.195 µM & 0.65 µM,
P<0.05), which was blocked in presence of the SIS. D) The APS was decreased at the highest dose, which
was blocked by the SIS. E) The mean lifespan was reduced at the highest dose (0.65 µM) from 18 days
to 14 days (-22%, P<0.05), which was blocked in presence of the SIS. The mean lifespan was reduced by
the SIS only from 18 days to 14 days (-24%, P<0.05). * indicates statistical significance, # indicates SIS
plus OP50 vs. OP50 only.
107

The fluorescent intensity of GFP-DAergic neurons was not altered at all doses (P>0.05), which
was reduced at high doses (0.195 µM & 0.65 µM, P<0.05) in presence of the SIS (Figure 36b). The size
of GFP-DAergic neurons was increased at all doses (0.065 µM, 0.195 µM & 0.65 µM, P<0.05), which
was blocked in presence of the SIS (Figure 36c). The APS was decreased at the highest dose, which was
blocked by the SIS (Figure 36d). The mean lifespan was reduced at the highest dose (0.65 µM) from 18
days to 14 days (-22%, P<0.05), which was blocked in presence of the SIS. The mean lifespan was reduced
by the SIS only from 18 days to 14 days (-24%, P<0.05, Figure 36e).
Dolichos biflorus agglutinin (DBA)-rhodamine did not show co-localization with GFP-DAergic
neurons but affected the DAergic neurons. The number of DAergic neurons was not altered, but was
increased at the highest dose (0.18 µM, P<0.05) in presence of the SIS GalNAc (50 mM, Figure 37a).
The fluorescence intensity of GFP-DAergic neurons was increased at the lowest dose (0.018 µM, P<0.05),
which was reversed by the SIS, and was increased at higher doses (0.054 µM & 0.18 µM, P<0.05) in
presence of the SIS (Figure 37b). The size of GFP-DAergic neurons was increased in a dose-dependent
trend at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05), which was blocked by the SIS (Figure 37c).
The APS was increased by lower doses of DBA, and decreased by higher doses (Figure 37d). The mean
lifespan was reduced at the highest dose (0.18 µM) from 19 days to 11 days (-43%, P<0.05). The animals
did not survive in presence of GalNAc (50 mM) within two days, possibly because of UDP depletion
(Figure 37e).
Galanthus nivalis agglutinin (GNA)-rhodamine did not show co-localization with GFP-DAergic
neurons or affect the DAergic neurons. The number of DAergic neurons was not altered with or without
the SIS mannose (34 mM, Figure 38a). The fluorescence intensity of GFP-DAergic neurons was not
altered at all doses, which was reduced at the medium dose (0.231 µM, P<0.05) in presence of the SIS
(Figure 38b).
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Figure 37. DBA-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The
number of DAergic neurons was not altered, but was increased at the highest dose (0.18 µM, P<0.05) in
presence of the SIS GalNAc (50 mM). B) The fluorescence intensity of GFP-DAergic neurons was
increased at the lowest dose (0.018 µM, P<0.05), which was reversed by the SIS, and was increased at
higher doses (0.054 µM & 0.18 µM, P<0.05) in presence of the SIS. C) The size of GFP-DAergic neurons
was increased in a dose-dependent trend at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05), which
was blocked by the SIS. D) The APS was increased at lower dose, and decreased at higher doses. E) The
mean lifespan was reduced at the highest dose (0.18 µM) from 19 days to 11 days (-43%, P<0.05). The
animals did not survive in presence of GalNAc (50 mM) within two days. * indicates statistical
significance, # indicates SIS plus OP50 vs. OP50 only.
The size of GFP-DAergic neurons was increased at all doses (0.077 µM, 0.231 µM & 0.77 µM,
P<0.05), which was blocked by the SIS (Figure 38c). The APS was reduced at all doses, which was
enhanced by the SIS (Figure 38d). The mean lifespan was reduced at higher doses (0.077 µM & 0.231
µM) from 24 days to 20 days and 19 days (-16% & -23%, P<0.05), which was enhanced in presence of
the SIS (Figure 38e).
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Figure 38. Galanthus nivalis agglutinin (GNA)-rhodamine did not show co-localization with GFPDAergic neurons or affect the DAergic neurons. A) The number of DAergic neurons was not altered with
or without the SIS mannose (34 Mm). B) The fluorescence intensity of GFP-DAergic neurons was not
altered at all doses, which was reduced at the medium dose (0.231 µM, P<0.05) in presence of the SIS.
C) The size of GFP-DAergic neurons was increased at all doses (0.077 µM, 0.231 µM & 0.77 µM, P<0.05),
which was blocked by the SIS. D) The APS was reduced at all doses, which was enhanced by the SIS. E)
The mean lifespan was reduced at higher doses (0.077 µM & 0.231 µM) from 24 days to 20 days and 19
days (-16% & -23%, P<0.05), which was enhanced in presence of the SIS. * indicates statistical
significance. * indicates statistical significance.
Griffonia Simplicifolia (GSL I)-TRITC did show co-localization but affected the DAergic neurons
in C. elegans. The number of the GFP-DAergic neurons was not altered (Figure 39a). The fluorescence
intensity of GFP-dopamine transporter protein in DAergic neurons was dose-dependently increased at all
doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05), which was augmented at lower doses (0.018 µM &
0.054 µM, P<0.05) and mitigated at the highest dose (0.18 µM, P<0.05, Figure 39b) by the SIS galactose
(40 mM). The size of GFP-DAergic neurons was not altered, but was dose-dependently increased at all
doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05) in presence of the SIS (Figure 39c). The APS was dose110

dependently decreased at all doses, which was reversed by SIS (Figure 39d). The mean lifespan was
decreased at the highest dose (0.18 µM) from 17 days to 10 days (-37%, P<0.05), which was blocked by
the SIS (Figure 39e).

Figure 39. GSL I-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The
number of the GFP-DAergic neurons was not altered. B) The fluorescence intensity of GFP-dopamine
transporter protein in DAergic neurons was dose-dependently increased at all doses (0.018 µM, 0.054 µM
& 0.18 µM, P<0.05), which was augmented at lower doses (0.018 µM & 0.054 µM, P<0.05) and mitigated
at the highest dose (0.18 µM, P<0.05) by the SIS galactose (40 mM). C) The size of GFP-DAergic neurons
was not altered, but was dose-dependently increased at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05)
in presence of the SIS. D) The APS was dose-dependently decreased at all doses, which was blocked by
SIS. E) The mean lifespan was decreased at the highest dose (0.18 µM) from 17 days to 10 days (-37%,
P<0.05), which was blocked by the SIS. *indicates statistical significance.
Hippeastrum hybrid agglutinin (HHA)-TRITC did show co-localization but affected the DAergic
neurons in C. elegans. The number of the GFP-DAergic neurons was not altered with or without the SIS
mannose (10 mM, Figure 40a). The fluorescence intensity of GFP-dopamine transporter protein in
DAergic neurons was increased at all doses (0.04 µM, 0.12 µM & 0.4 µM, P<0.05), which was blocked
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at lower doses (0.04 µM & 0.12 µM, P>0.05) and reversed at the highest dose (0.2 µM, P<0.05) in
presence of the SIS (Figure 40b).

Figure 40. HHA-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The
number of the GFP-DAergic neurons was not altered with or without the SIS mannose (10 mM). B) The
fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was increased at all doses
(0.04 µM, 0.12 µM & 0.4 µM, P<0.05), which was blocked at lower doses (0.04 µM & 0.12 µM, P>0.05)
and reversed at the highest dose (0.2 µM, P<0.05) in presence of the SIS. C) The size of GFP-DAergic
neurons was increased at the lowest dose (0.04 µM, P<0.05), which was reversed in presence of the SIS
and reduced at the highest dose (0.4 µM, P<0.05) in presence of the SIS. D) The APS was dosedependently decreased at all doses. E) The mean lifespan was decreased at higher doses (0.12 µM& 0.4
µM) from 21 days to 15 days and 11 days (-29% & -47%, P<0.05), which was blocked at the medium
dose (0.12 µM) in presence of the SIS. * indicates statistical significance.
The size of GFP-DAergic neurons was increased at the lowest dose of HHA (0.04 µM, P<0.05),
which was reversed in presence of the SIS and reduced at the highest dose (0.4 µM, P<0.05) in presence
of the SIS (Figure 40c). The APS was dose-dependently decreased at all doses (Figure 40d). The mean
lifespan was decreased at higher doses (0.12 µM& 0.4 µM) from 21 days to 15 days and 11 days (-29%
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& -47%, P<0.05), which was blocked at the medium dose (0.12 µM) in presence of the SIS (Figure 40e).
Phaseolus vulgaris agglutinin-L (PHA-L)-TRITC did show co-localization but affected the
DAergic neurons in C. elegans. The number of the GFP-DAergic neurons was not altered with or without
the SIS GalNAc (1.58 mM, Figure 40a). The fluorescence intensity of GFP-dopamine transporter protein
in DAergic neurons was reduced at lower doses (0.017 µM & 0.051 µM, P<0.05), which was reduced at
the highest dose (0.17 µM, P<0.05) in presence of the SIS (Figure 40b).

Figure 41. PHA-L-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A)
The number of the GFP-DAergic neurons was not altered with or without the SIS GalNAc (1.58 mM). B)
The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was reduced at lower
doses (0.017 µM & 0.051 µM, P<0.05), which was reduced at the highest dose (0.17 µM, P<0.05) in
presence of the SIS. C) The size of GFP-DAergic neurons was increased at all doses (0.017 µM, 0.051
µM & 0.17 µM, P<0.05), which was blocked at the highest dose (0.17 µM) in presence of the SIS. D)
The APS was increased at low dose and reduced at higher doses. E) The mean lifespan was reduced at
the highest dose (0.17 µM) from 20 days to 13 days (-34%, P<0.05), which was increased at the lowest
dose (0.017 µM) in presence of the SIS. * indicates statistical significance.
The size of GFP-DAergic neurons was increased at all doses (0.017 µM, 0.051 µM & 0.17 µM,
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P<0.05), which was blocked at the highest dose (0.17 µM) in presence of the SIS (Figure 40c). The APS
was increased at low dose and reduced at higher doses (Figure 40d). The mean lifespan was reduced at
the highest dose (0.17 µM) from 20 days to 13 days (-34%, P<0.05), which was increased at the lowest
dose (0.017 µM) in presence of the SIS (Figure 40e).
Soybean agglutinin (SBA)-TRITC did show co-localization but affected the DAergic neurons in
C. elegans (Figure 42).

Figure 42. Soybean agglutinin (SBA)-TRITC did show co-localization but affected the DAergic neurons
in C. elegans. A) The number of the GFP-DAergic neurons was decreased at the lowest dose (0.017 µM,
P<0.05), which was blocked by the SIS GalNAc (12.5 mM). B) The intensity of DAergic neurons was
not altered at all doses (P>0.05), which was increased at the lowest dose (0.017 µM, P<0.05) and reduced
at the highest dose (0.17 µM, P<0.05) in presence of the SIS. C) The size of GFP-DAergic neurons was
reduced at the lowest dose (0.017 µM, P<0.05), which was blocked in the presence of the SIS. D) The
APS was slightly increased at low doses and reduced at higher dose. E) The mean lifespan was reduced
at the highest dose (0.17 µM) from 20 days to 14 days (-31%, P<0.05), which was blocked by the SIS.
The mean lifespan was reduced by the SIS only from 20 days to 11 days (-48%, P<0.05). * indicates
statistical significance, # indicates SIS plus OP50 vs. OP50 only.
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The number of the GFP-DAergic neurons was decreased at the lowest dose (0.017 µM, P<0.05),
which was blocked by the SIS GalNAc (12.5 mM, Figure 42a). The fluorescence intensity of GFPdopamine transporter protein in DAergic neurons was not altered at all doses (P>0.05), which was
increased at the lowest dose (0.017 µM, P<0.05) and reduced at the highest dose (0.17 µM, P<0.05) in
presence of the SIS (Figure 42b). The size of GFP-DAergic neurons was reduced at the lowest dose (0.017
µM, P<0.05), which was blocked in the presence of the SIS (Figure 42c). The APS was slightly increased
at low doses and reduced at higher dose (Figure 42d). The mean lifespan was reduced at the highest dose
(0.17 µM) from 20 days to 14 days (-31%, P<0.05), which was blocked by the SIS. The mean lifespan
was reduced by the SIS only from 20 days to 11 days (-48%, P<0.05, Figure 42e).
Concanavalin A (Con A)-TRITC did not show co-localization with but affected GFP-DAergic
neurons in C. elegans. The number of DAergic neurons was not altered with or without the SIS αmethylmannoside (200 mM) plus α-methylglucoside (200 Mm, Figure 43a). The fluorescence intensity
of GFP-dopamine transporter protein image in DAergic neurons was increased at the highest dose (0.19
µM, P<0.05) and reversed by the SIS (P<0.05, Figure 43b). The size was reduced at middle dose (0.057
µM, P<0.05), which was blocked by the SIS (Figure 43c). The APS was increased at all doses, which
was blocked by the SIS (Figure 43d). The mean lifespan was not altered with or without SIS (Figure 43e).
Cicer arietinum agglutinin (CPA)-TRITC did not show co-localization with but affected GFPDAergic neurons in C. elegans. The number of DAergic neurons was not altered with or without the SIS
bovine fetuin (0.77 µM, Figure 44a). The fluorescence intensity of GFP-dopamine transporter protein
image in DAergic neurons was reduced at the doses (0.047 µM & 0.47 µM, P<0.05), which was blocked
at the lowest dose (0.047 µM) by the SIS (Figure 44b). The size was reduced at middle at the doses (0.047
µM & 0.47 µM, P<0.05), which was blocked by the SIS (Figure 44c). The APS was increased at all doses,
which was reversed by the SIS (Figure 44d). The mean lifespan was not altered by CPA, which was
decreased by CPA from 29 days to 22 days and 11 days (-25% & -64%, P<0.05) in presence of the SIS.
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The mean lifespan was increased by the SIS only from 23 days to 29 days (28%, P<0.05, Figure 44e).

Figure 43. Con A-rhodamine affected the GFP-DAergic neurons in C. elegans. A) The number of
DAergic neurons was not altered with or without the SIS α-methylmannoside (200 mM) plus αmethylglucoside (200 Mm). B) The fluorescence intensity of GFP-dopamine transporter protein image
in DAergic neurons was increased at the highest dose (0.19 µM, P<0.05) and reversed by the SIS (P<0.05).
C) The size was reduced at middle dose (0.057 µM, P<0.05), which was blocked by the SIS. D) The APS
was increased at all doses, which was blocked by the SIS. E) The mean lifespan was not altered with or
without SIS. * indicates statistical significance.
Solanum tuberosum agglutinin (STA)-TRITC did not show co-localization with but affected GFPDAergic neurons in C. elegans. The number of DAergic neurons was not altered with or without the SIS
chitin hydrolystate (2.5%, Figure 45a). The fluorescence intensity of GFP-dopamine transporter protein
image in DAergic neurons was not altered (Figure 45b).
The size was reduced at all doses of STA (0.02 µM, 0.06 µM & 0.2 µM, P<0.05), which was
blocked by the SIS (Figure 45c). The APS was slightly increased without the SIS (Figure 45d). The mean
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lifespan was not altered by STA. The animals died within one week of adding treatments. The mean
lifespan was decreased by the SIS only from 22 days to 10 days (-54%, P<0.05, Figure 45e).

Figure 44. CPA-TRITC did not show co-localization with but affected GFP-DAergic neurons in C.
elegans. A) The number of DAergic neurons was not altered with or without the SIS bovine fetuin (0.77
µM). B) The fluorescence intensity of GFP-dopamine transporter protein image in DAergic neurons was
reduced at the doses (0.047 µM & 0.47 µM, P<0.05), which was blocked at the lowest dose (0.047 µM)
by the SIS. C) The size was reduced at middle at the doses (0.047 µM & 0.47 µM, P<0.05), which was
blocked by the SIS. D) The APS was increased at all doses, which was reversed by the SIS. E) The mean
lifespan was not altered by CPA, which was decreased by CPA from 29 days to 22 days and 11 days (25% & -64%, P<0.05) in presence of the SIS. The mean lifespan was increased by the SIS only from 23
days to 29 days (28%, P<0.05). * indicates statistical significance, # indicates SIS plus OP50 vs. OP50
only.
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Figure 45. STA-TRITC did not show co-localization with but affected GFP-DAergic neurons in C. elegans.
A) The number of DAergic neurons was not altered with or without the SIS chitin hydrolystate (2.5%).
B) The fluorescence intensity of GFP-dopamine transporter protein image in DAergic neurons was not
altered. C) The size was reduced at all doses (0.02 µM, 0.06 µM & 0.2 µM, P<0.05), which was blocked
by the SIS. D) The APS was slightly increased without the SIS. E) The mean lifespan was not altered by
STA. The animals died within one week of adding treatments. The mean lifespan was decreased by the
SIS only from 22 days to 10 days (-54%, P<0.05). * indicates statistical significance, # indicates SIS plus
OP50 vs. OP50 only.
1.4

Discussion
The purpose of the specific inhibiting sugar was to bind with, and then block the corresponding

lectins. As stated in the beginning of this chapter, using high concentration of sugars would cause various
other effects other than binding with lectins in the C. elegans organism, like UDP depletion causing the
ceasing of RNA synthesis. In the current study, SIS was observed to have various effects when
supplemented with lectins in liquid culture.
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The interaction between lectins and specific sugars is complicated, depending on properties of the
sugar-binding sites in lectins and the moieties in the sugars. Lectins have several sugar-binding sites
available due to the repeat of sequences, some lectins like EEA and PNA bind to monosaccharide, other
lectins like ACA and CSA bind to polysaccharides. The sequence of amino acids in the sugar-binding
sites of the lectins has an important role in selecting the specific sugars [16]. The binding between lectins
and simple sugars is not as strong as between lectins and polysaccharides, but the multiple binding sites
in simple sugars produce multivalent bindings with lectins [17], which increases the affinity of simple
sugars and lectins to some extent. The dissociation constant of lectin Con A from glycoprotein asialofetuin
increases as the concentration of inhibiting sugars increases [18], which suggest that the binding between
the sugars and lectins is reversible; the existence of the third compound may compete with sugars for the
binding with lectins.
1.4.1 SIS inhibited the effects of lectins on GFP-DAergic neurons or mean lifespan
SIS were observed to block the effects caused by lectins on the GFP-DAergic neurons or mean
lifespan. The possible explanation is that the sugar binding sites of lectins were covered by the SIS first,
which prevented the binding of lectins with other receptors on cell surface in C. elegans organism. The
effect of ACA (0.096 µM) on reducing the size of GFP-DAergic neurons was blocked by the SIS GalNAc,
which might be due to the binding of SIS with ACA. The observation that the SIS GalNAc did not block
the effects of the highest dose of ACA (0.32 µM) might suggest the concentration of the SIS was not high
enough to bind to all sugar binding sites of ACA. Similarly, the SIS GalNAc only blocked the effects of
lowest dose of ACA (0.032 µM) on reducing the mean lifespan but not on higher doses.
1.4.2 SIS mitigated the effects of lectins on GFP-DAergic neurons or mean lifespan
Some SIS were observed to alleviate the effects of lectins in C. elegans. The reason that the SIS did
not block the effect but only mitigated the effects might be due to the partial binding of the SIS with sugar
binding sites of lectins. The highest dose of EEA (0.48 µM) increased the size of GFP-DAergic neurons;
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the adding of the SIS lactose did not block these effects but only reduced the magnitude. The effect of
medium dose of EEA (0.136 µM) on reducing the mean lifespan was mitigated by the SIS.
1.4.3 SIS affected the effects of lectins on GFP-DAergic neurons or mean lifespan
SIS were also observed to enhance or the effects of SIS on lectins in C. elegans. Lower doses of
GSL I (0.018 & 0.054 µM) increased the fluorescence intensity of GFP-dopamine transporter protein
image in DAergic neurons, with the SIS galactose present, these effects of increasing was strengthened.
In addition, the SIS reversed the effect of the highest dose of Con A on increasing the fluorescence
intensity of GFP-dopamine transporter protein image in DAergic neurons. These findings were not caused
by the effects of lectins only; the possible explanation might be due to some unknown effects caused by
the SIS or the interactions between the SIS and lectins.
The fact that only certain doses reduced the number of DAergic neurons but other doses did not
suggests that this effect is dose-related. The presence of lactose (10 mM) blocked this effect probably
because lactose bound with the binding sites of EEA, thus reduced the activity of EEA. In contrast to
EEA, low doses of S-WGA reduced the number of DAergic neurons while the highest dose did not.
Similarly, this effect was blocked by the presence of the SIS chitin hydrolysate (2.5%), probably due to
the same mechanism as EEA. The effects of CSA and SBA on reducing the number of DAergic neurons
were also blocked by their SISs. The reduction of neuron numbers indicated the toxicity of these lectins,
which was consistent with the lifespan results, that both EEA and S-WGA reduced the mean lifespan
significantly. The lectin LcH increased the number of DAergic neurons at both the lowest dose and the
highest dose. These effects were either blocked at low dose or reversed at high dose by the SIS, which
implied that high dose of the SIS had detrimental effects.
The toxic effects of high concentration of sugars in C. elegans were expected, and lower
concentration of sugars would not be enough to counteract the effects of lectins. The present study showed
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that the SIS blocked the effects caused by lectins on GFP-DAergic neurons or mean lifespan, whereas,
other effects might be due to the toxic effects of the SIS.
1.5
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CHAPTER IV. DIETARY BIOACTIVE COMPOUNDS MAY AFFECT LIFESPAN AND
FAT STORAGE ASPECTS IN C. ELEGANS
1.1

Introduction
Health determines human lifespan as well as optimal quality of life [1, 2]. Aging at the cellular level

involves complex interacting mechanisms that lead to functional declines which become manifest
following birth and proceed through life. A U.S. population based study demonstrated that mortality risk
was directly correlated with body mass index (BMI). Thus, above 25 kg/m2, BMI inversely correlated
with lifespan [3]. The increasing age of western societies creates a greater burden of chronic diseases
including cancer, cardiovascular disease, diabetes, and neurodegenerative disorders including PD and
Alzheimer's disease [4-8], leading to a high cost of health care and a great financial burden to the public
health system and families [9, 10]. Among complex factors, both obesity and aging decrease insulin
sensitivity, impair the immune response, increase inflammation, impair the gut-bloodstream barrier, and
decrease physical mobility [11]. Many dietary interventions provide noninvasive approaches to reinforce
optimal nutrition, fight metabolic dysfunction, enhance physiological function, and promote a healthy
lifespan [12-14].
Dietary polyphenol antioxidants play important roles in health [15-19]. Pomegranates (Punica
granatum L.) have a high content of polyphenols (1.5%), including ellagic acid (EA), gallic acid,
anthocynidins, flavan-3-ols, straight chain fatty acids, citric acid, and malic acid. Pomegranates consist
of about 80% of juice and 20% of seeds with water (85%), and 10% sugars consisting primarily of fructose
(2.5 g to 17.6 g/100ml) [20, 21] (Table 6). PJ has been shown to extend lifespan in mice [22, 23] and
Drosophila melanogaster [24]. PJ extract (POMx) potentiates lifespan extension with dietary restriction,
a finding attributed by polyphenols [22, 23]. POMx and PJ can also act as prebiotics, having demonstrated
antibacterial properties in vitro, and can block DNA repair and inhibit proliferation of breast cancer cells
(MCF-7) in vitro, as well as modulate the IGF-IGFBP axis [25-29]. POMx and PJ also down-regulate
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androgen-synthesizing genes to induce apoptosis of human prostate cells (kappaB-dependent) in vitro and
in mice in vivo [30-33]. POMx and PJ decrease prostate specific antigen in humans after surgery or
radiation [34, 35], inhibit tumor-associated angiogenesis in vitro and in vivo [34], suppress inflammatory
cell signaling in colon cancer cells [36] (50 mg/L PJ, in vitro), improve memory [37] and improve
fecundity in humans [24, 38-40].
As the main bioactive component, EA is a measure of the quality of PJ extract products [39, 41, 42].
EA in humans reaches a maximum plasma level in 1 hour (31.9 ng/ml), is eliminated within 4 hours [43]
and exerts an antioxidant effect [44]. Urolithin acid (UA) is the main active metabolite of EA and is
formed by the colonic microflora. UA lasts longer in the human body than EA or other EA metabolites
[26, 45], and has better bioavailability [46]. UA also suppresses colorectal, hepatic, and prostate cancers
synergistically with EA in vitro and in mice in vivo [47-51].
Table 6. Nutrition facts of pomegranate juice
Serving size 8 fl. oz. (236 mL)
Amounts per serving
Calories
150
Calories from Fat
0
% Daily Value
Total Fat 0 g
0%
Saturated Fat 0 g
0%
Trans Fat 0 g
Cholesterol l0 mg
Sodium 0 mg
0%
Potassium 600 mg
17%
Total Carbohydrate 36 g
12%
Fiber 0 g
0%
Sugars 31 g
Protein 1 g
Vitamin A
<2%
Vitamin C
<2%
Calcium
<2%
Iron
0%
Percent Daily Values are based on a 2,000 calorie diet

124

C. elegans model organism is the first animal model to have its genome completely sequenced. C.
elegans conserves 65% of the genes associated with human diseases, and has been increasingly used for
functional biomedical research with more than 300 transgenic and mutant strains available [52-62]. The
C. elegans daf-16 gene, a homologue of the human gene FOXO, regulates C. elegans lifespan and
mediates both lipid metabolism and insulin signaling pathways [63, 64].
We hypothesized that pomegranate would increase lifespan while reducing intestinal fat deposition
(IFD). We evaluated four PJ products using the C. elegans wild type (N2) to assess their effect on lifespan
and IFD, and to predict their potential effect on aging and obesity in humans. In addition, we also used a
daf-16 deficient mutant to assess the role of the FOXO signaling pathway in mediating the effects of
botanicals evaluated.
1.2

Materials and methods
C. elegans strains wild type (N2) and daf-16 mutant (daf-16(mgDf50)I) GR1307, and their standard

lab food, Escherichia coli (E. coli, OP50, Uracil auxotroph), were obtained from the Caenorhabditis
Genetics Center (University of Minnesota, Minneapolis, MN). PJ (POM Wonderful® LLC, Los Angeles,
CA, USA) was purchased from a local grocery store. POMx (extract of pomegranate) was a gift from
POM Wonderful® LLC (Los Angeles, CA, USA). EA was purchased from Sigma (St. Louis, MO, USA).
UA was synthesized by Dr. David Heber’s laboratory [65].
1.2.1 Culture of C. elegans
Mature gravid wild type C. elegans (N2, Bristol) and daf-16 deficient mutant [daf-16(mgDf50)I]
were treated with NaOH (1M) and sodium hypochlorite solution (5.25%, 5:2 ratio) to dissolve the body
and release viable eggs [61]. The eggs were hatched overnight after washing with S-complete solution
three times. The age-synchronized C. elegans were diluted to 100 animals/ml, plated in liquid culture in
a 96-well plate (120 μl/well, 10-15 animals) [66] with OP50 (109 cfu/ml), and incubated in 20C (N2) or
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15C (daf-16 mutant) low temperature incubators (Revco Tech., Nashville, NC, USA). Thirty microliters
of 5-Fluoro-2′-deoxyuridine (FUDR, 0.6mM) stock solution was added to each well at Larvae 4 stage.
1.2.2 Culture of Escherichia coli (E. coli, OP50)
OP50 were cultured by the standard method described elsewhere [61]. Briefly, approximately 10
µL of stock E. coli solution was added to media and incubated at 37°C for 24h. The OP50 were then
plated in PetrifilmTM (3M Corporate, St. Paul, MN) at 37°C for 24 h until densities of 5×108 to 5×1011
colony forming units (cfu/ml) were reached and then were fed to the C. elegans ad libitum [61, 67]. The
OP50 stock feeding solution was enriched to 2×109 cfu/ml by centrifuging at 2,200 g for 10 minutes and
washed with S-complete buffer twice.
1.2.3 Lifespan assays
Fifty microliters of the treatments was added to each well three days after egg-synchronization. The
control group received OP50 only. The experimental groups received additional PJ (0.01%, 0.1%, 1%,
3%, 5%, 10% or 25%, v/v), POMx (5, 10, 20, 40, 80, 160, and 320 µg/ml), EA (1, 2, 5, 10, 25, and 50 µM
in dimethyl sulfoxide (DMSO 0.05%), or UA (1, 2, 5, 10, 25, and 50 µM in DMSO) (n=10-15/well/6well).
A second control (DMSO, 0.05%) was used in the EA and UA groups. Additional OP50 was added to
each well every other week until all animals were dead. The numbers of live animals were manually
recorded every other day under a microscope (Nikon, Eclipse Ti –S, Japan).
1.2.4 Fluorescence microscopy
Same treatments as in lifespan assay were added to each well at larvae 1 stage of animals. Lipophilic
dye, Nile red, was used to stain for IFD, and fluorescent intensity was evaluated [61]. C. elegans in each
group were collected after 3 days of treatments, washed with S-Basal twice, fixed with paraformaldehyde
(4%) over 2h at 4°C and washed with PBS for 5 min x 3. Nile red (50 µL) was applied to the specimens
for 10 min. Ten microliters of Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL)
was applied to a glass slide followed by 20 µL of the medium containing Nile red stained C. elegans. A
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cover glass was mounted on the glass slide, and the slides were viewed with an epifluorescence
microscope (Nikon Eclipse, Ti) equipped with a Texas Red filter. Fluorescent micrographs were taken
with a digital camera (Andor, DU-885k) and analyzed using Nikon-Elements (version 3.22.11). Optical
densities (arbitrary units) of Nile red stained IFD were determined for C. elegans (larvae 4).
1.2.5 Statistical Analysis
Analyses were carried out using SAS/STAT® software, Version 9.4 of the SAS System for
Windows (Cary, NC, USA). All results were expressed as mean±S.E.M. Survival curves were displayed
by binomial probabilities obtained from logistic regression models as surrogates for survival probabilities
and mean lifespan was estimated via Kaplan-Meier (log-rank). ANOVA models with post hoc Tukey
adjustment were used to analyze fluorescence intensity data. Statistical significance was defined as
P<0.05.
1.3

Results
PJ treatment dose-dependently extended the mean lifespan of N2 up to 56% or daf-16 mutant up to

30% in an A-shape curve, the magnitude of the lifespan extension was decreased at higher doses. A
similar trend with half the magnitude was observed in POMx treated animals in N2 (28%). EA or UA did
not significantly affect lifespan overall, however, lifespan extension was observed in several days of the
experiment in each treatment (Supplement Table 8c & d). The fluorescent intensity of IFD in C. elegans
was reduced by PJ treatment in N2 (-68%) or in daf-16 (-33%). In contrast, IFD was increased in N2
more than in the daf-16 mutant by POMx (137% at 320 µg/ml vs. 26% at 20 µg/ml), or UA (57% at 10
µM vs. 43% at 50 µM). IFD was increased by EA in N2 (66% at 5 µM) and in daf-16 mutant (74% at 25
µM).
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1.3.1 PJ dose-dependently extended then reduced lifespan in N2 and the daf-16 mutant
In a dose-dependent manner, PJ added to the cultures significantly increased mean lifespan in N2
up to the 1% dose but produced reduced lifespans at higher doses, an A-shape curve relationship (Figure
46a & b).

Figure 46. In an A-shape, PJ dose-dependently increased lifespan in both N2 (a & b) and daf-16 mutant
(c & b) at lower doses, and dose-dependently reduced it at higher doses. PJ dose-dependently reduced the
fluorescent intensity of IFD (arbitrary unit) in N2 and daf-16 mutant (d). *P<0.05
The average probability of survival across the lifespan was increased by lower doses of PJ (0.01%,
0.1%, & 1%, P<0.05), while lifespan was decreased at higher doses (10% & 25%, P<0.05, Figure 46a).
The mean lifespan was increased at lower doses (0.1% - 1%) from 21 to 33 days (42% - 56%, P<0.05)
while it was decreased at higher doses (10% & 25%) from 33 to 4 days (-67% & -81%, P<0.05) (Figure
46b). Similarly, in the daf-16 mutant, PJ also significantly increased mean lifespan in a dose-dependent
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manner up to 5 % after which survival was significantly reduced. The dose-response curve shifted to the
right. The APS across the lifespan of the daf-16 mutant was increased at lower doses (1%, 3%, & 5%,
P<0.05) and reduced at higher doses (10% & 25%, P<0.05, Figure 46c). The mean lifespan of the daf-16
mutant was increased from 27 to 32 days at a dose (5%) that reduced lifespan in N2 (18%, P<0.05) and
decreased at the higher doses (-61% at 10% & -49% at 25%, P<0.05, Figure 46b). Additionally, specific
days during the experiment at which significant differences in survival probabilities were observed are
provided (Supplement Table 8a).
PJ dose-dependently reduced the fluorescent intensity of IFD in N2 and the daf-16 mutant (L4). In
N2, the IFD was reduced from 6971607 to 2372245 (-30% at 1%, -44% at 3%, -66% at 5%, -68% at
10% & -55% at 25%, n=10, P<0.05). The IFD was increased at lower doses in the daf-16 mutant from
4677136 to 7222240 (54% at 0.01%, 28% at 0.1%, n=10, P<0.05), followed by reduction at higher
doses to 3134252 (-24% at 1%, -21% at 5% & -33% at 25%, n=10, P<0.05) (Figure 46d).
1.3.2 POMx dose-dependently increased lifespan in N2 and in the daf-16 mutant
A dose-response curve for lifespan extension was also present in the N2 group treated with POMx,
but was absent in the daf-16 mutant. In N2, the APS across the lifespan was increased at all doses (5, 10,
20, 40, 80, 160, & 320 µg/ml, P<0.05, Figure 47a). The mean lifespan was elevated from 18 to 22 days
(18% at 10 μg/ml & 28% at 20 μg/ml, P<0.05, Figure 47b). The APS across the lifespan of the daf-16
mutant was increased at lower doses (5, 10, & 40 g/ml, P<0.05) and reduced at the highest dose (320
g/ml, P<0.05, Figure 47c). The mean lifespan of the daf-16 mutant was not altered (Figure 47b).
Additionally, specific days during the experiment at which significant differences in survival probabilities
were observed are provided (Supplement Table 8b).
In N2, lower doses of POMx slightly reduced the IFD (P>0.05) followed by an increase from
3323±63 to 7515±125 at the highest dose (137% at 320 µg/ml, n=10, P<0.05). Similarly in the daf-16
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mutant, POMx increased the IFD from 5012±1032 to 6327±716 at mid-dose (26% at 20 µg/ml, n=10,
P<0.05) followed by a reduction to 3815±736 at a higher dose (23.9% at 80 µg/ml, n=10, P<0.05) (Figure
47d).

Figure 47. An A-shape dose-responses of lifespan extension was present in POMx treated group in both
N2 (a & b) and the daf-16 mutant (c & b), however, POMx was less potent than PJ. In N2, had an initial
elevation of life span in the presence of lower doses of POMx which also reduced the IFD (d). IFD was
increase at the highest dose. In the daf-16 mutant, POMx increased IFD at mid-dose followed by a
reduction at a higher dose. *P<0.05
1.3.3 EA did not alter lifespan in N2 or in the daf-16 mutant
Unlike PJ and POMx that increased lifespan dose-dependently, EA did not alter lifespan in N2 or
the daf-16 mutant. There was a mild increase of lifespan in N2 at lower doses and a mild decrease at
higher doses (P>0.05, Figure 48a) with the mean lifespan also being unchanged (P>0.05, Figure 48b).
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Figure 48. EA did not alter lifespan in N2 (a & b) but increased the lifespan in the daf-16 mutant (c & b)
at the highest dose. The IFD (d) was dose-dependently elevated by EA in both N2 and daf-16 mutant, and
the responses were in parallel with a greater elevation (by 2-fold) in the daf-16 mutant. *P<0.05
The APS of the daf-16 mutant was elevated at the highest dose (50M, P<0.05, Figure 48c), but the
increase in mean lifespan was not significant (P>0.05, Figure 48b). The specific days during the
experiment at which significant differences in survival probabilities were observed are provided
(Supplement Table 8c). The IFD elevation by EA was dose-dependent, similar in both N2 and the daf-16
mutant, and in parallel with a 2-fold elevation in the daf-16 mutant. In N2, EA increased IFD from
5190±158 to 8608±323 at higher doses (66% at 5 µM, 59% at 10 µM, 58% at 25 µM, & 47% at 50 µM,
n=10, P<0.05). Similarly in the daf-16 mutant, EA increased IFD at the higher doses from 8237±227 to
14324±113 (60% at 10 µM, 74% at 25 µM, & 49% at 50 µM, n=10, P<0.05) (Figure 48d).
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1.3.4 UA did not alter lifespan in N2 or in the daf-16 mutant
As with EA, UA did not alter the lifespan in N2 or the daf-16 mutant. In N2, the APS across the
lifespan was increased at the highest dose (50 M, P<0.05, Figure 49a).

Figure 49. The mean lifespan was increased in N2 (a & b) but decreased in daf-16 mutant (c & b) in UA
treated group. Animals treated with UA had an increased IFD (d) in both N2 and the daf-16 mutant with
a parallel pattern of response with N2 showing a greater increase than the daf-16 mutant. *P<0.05
The mean lifespan was not changed (P>0.05, Figure 49b). The APS across the lifespan of the daf16 mutant was reduced at doses (1, 25, & 50 M, P<0.05, Figure 49c), while the mean lifespan was not
changed (P>0.05, Figure 49b). Additionally, specific days during the experiment at which significant
differences in survival probabilities were observed are provided (Supplement Table 8d). The IFD was
increased in N2, from 1362±61 to 6278±991 in the DMSO-control group (361% at 0.05% DMSO, n=10,
P<0.05) and greater elevation to 9860±216 was observed at higher doses (57% at 10 µM, 47% at 25 µM,
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& 46% at 50 µM, n=10, P<0.05). The IFD in the daf-16 mutant was increased from 3021±127 to
4324±177 dose-dependently (34% at 10 µM & 43% at 50 µM, n=10, P<0.05) (Figure 49d).
1.4

Discussion
Our findings reveal that the lifespan extension has the same trend, either on a larger or on a smaller

scale, in N2 and the daf-16 mutant by treatment with PJ or POMx, and with minimal effects on lifespan
in cultures treated with EA or UA. These results indicated that the daf-16 pathway was partially required
for lifespan extension in the present study. The survival curves displayed are approximated by estimated
probabilities of survival across the lifespan (Binomial). Although some treatment groups show
statistically significant differences, comparisons based on these probabilities cannot be used to draw
conclusions regarding lifespan.
As energy sources, appropriate amount of sugar should have beneficial effects on lifespan
extension. However, high sugar (>2%) in the diet is detrimental to the C. elegans and reduces lifespan
[62, 68-70]. The dose-response curves with an A-shape were seen in PJ and POMx treated animals. We
were puzzled by the fact that the lower doses of PJ increased lifespan, while the higher doses decreased
the lifespan. We wondered if this might be related to PJ’s high sugar content. We found that the reversal
of the lifespan extension by PJ was at a dose that contained 0.4% sugar (Table 7). PJ has a high content
of sugars in which the fructose is 1.25-fold greater than that of glucose which, in turn, is 4.7-fold higher
than that of mannitol [71]. In agar dish culture, extra glucose (>0.001% or 2%) reduces lifespan mainly
due to reducing signals of the DAF-16/FOXO and heat shock transcription factor (HSF-1) gene signaling
[72-76]. The effect of fructose, however, is controversial. Supplemental fructose reduces the plasma
glucose level, glycohemoglobin, serum cholesterol, triglycerides, lactate, and body weight in type 2
diabetes [75, 77]. Many epidemiological studies link the consumption of high dietary fructose usage to
an increased prevalence of obesity, which has been reported with lack of sufficient evidence. Since
associations do not show cause and effect, clinical trials are needed to support this hypothesized cause for
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obesity [78-80]. The A-shape dose-response relationship with the lifespan in the present studies appears
to be related to the increasing sugar content. On the other hand, the level of sugar tolerance may be speciedependent, since a diet supplemented with PJ (10%) increase lifespan of flies [24]. The data also implies
involvement of the daf-16 pathway, since the reduced lifespan was observed only at the highest dose in
the daf-16 mutant group. The A-shape curve of PJ showed the longest lifespan to be at a sugar content of
0.13% in N2 and 0.66% in the daf-16 mutant. The fact that PJ increased lifespan of the daf-16 mutant in
our study may indicate alternative mechanism. The lifespan curve shifting rightward might indicate an
“independent or compensatory effect of the daf-16 pathway”.
Table 7. Sugar content of the PJ feeding media
Doses [%]
Sugar [%]

0
0

0.01
0.1
1
3
5
10
25
0.001 0.013 0.13 0.39 0.66 1.31 3.28

Fat storage is one of the outcomes of energy consumption and energy expenditure in living
organisms. In C. elegans, the fluorescent intensity of IFD in the PJ group was reduced in both N2 and the
daf-16 mutant. This inverse relationship of lifespan and fat content (PJ 1%) is in agreement with studies
that PJ is effective in reducing cardiovascular risk factors in overweight humans [81].
POMx, extracted from PJ, which is characterized by rich polyphenols extracted from pomegranate,
extended the lifespan in a similar manner as PJ with an A-shape curve in N2. POMx in the daf-16 mutant
extended lifespan by several days (Supplement Table 8b). Unlike PJ, POMx did not reduce lifespan at
higher doses. These results may be attributed to either an absent or reduced sugar content and/or other
unknown factors. The effect of POMx on lifespan extension was only half the magnitude of the lifespan
extension induced by PJ, which suggests that multiple factors in the PJ products extend lifespan as was
suggested by the Heber’s studies [82]. Also unlike PJ, a V-shape dose-response curve was detected for
the IFD in POMx treated animals at the doses that were used in this study, and only a minimal reduction
of IFD was observed (P>0.05). The reversal of the pattern of increase in lifespan extension and decrease
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in IFD occurred at 80 g/ml, which seems to relate to the sugar content as it did in PJ treated group.
Elevating IFD in the daf-16 mutant suggests the involvement of this pathway controlling body fat
accumulation.
Unlike either PJ or POMx, EA did not alter lifespan in N2 or in the daf-16 mutant at the doses that
was used. Lifespan extension was observed on several days of the experiment, which is similar with a
study in N2 in agar culture that the EA (50 µM at 0.3% DMSO) prolonged mean lifespan [83].
DMSO is a solvent that extends lifespan dose-dependently in N2 with an “A-shape ” curve, in agar
culture (24% at 0.05% to 5%, v/v) [84] and in a liquid culture (20% at 0.9%, v/v) [85]. In the present
study, DMSO doses were limited to the minimum. The lower DMSO dose (0.05%) extended lifespan up
to 12.7%, while the higher amount (0.1%) decreased the lifespan which is different from the observations
of the Wang group [84], which observed a 30% reduction in lifespan in the daf-16 mutant (9.4%). The
effect of EA on extending lifespan suggested complex mechanisms involving daf-16 that is known as the
gene for lifespan in C. elegans. EA also dose-dependently increased IFD at higher doses in N2 with
parallel findings in the daf-16 mutant. The enhanced IFD in the daf-16 mutant uncovered the important
role of the daf-16 on lipid/energy metabolism, which was not seen in the PJ treated groups.
Like all polyphenols, EA’s large molecular weight and hydrophilic properties could have limited
the absorption in the intestine as well as the bioavailability to the hosts. Since the main metabolites of EA
have many beneficial effects, the effects of UA which is a metabolite of the colonic microbiota that has a
higher absorption index has attracted extensive research in recent years [86]. UA has anti-inflammatory,
anti-carcinogenic, anti-glycative, anti-oxidant, and anti-microbial effects [86-88]. In our study, some of
the treatment groups showed a statistically significant increase in mean survival probabilities in the
presence of UA. Although one cannot draw conclusions from these observations, it is possible that higher
doses of UA may alter lifespan, and the daf-16 mutant pathway is predicted to mediate the effect of UA
on lifespan. UA also dose-dependently increased IFD at higher doses in both N2 and in the daf-16 mutant,
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in parallel, with the latter having half the increase in IFD.
The antioxidant potency of PJ is higher (by at least 20%) compared to other polyphenol-rich
products including red wine, Concord grape juice, blueberry juice, black cherry juice, cranberry juice,
orange juice, iced tea beverages, and apple juice in vitro [89]. Thus, PJ has superior antioxidant bioactivity
compared to its purified polyphenols, EA, punicalagin, or total pomegranate tannin. These conclusions
are consistent with Seeram et al. who cited multifactorial effects and chemical synergy of the action of
multiple compounds in PJ compared to single purified active ingredients [82].
EA content varies by variety of the fruit, and many commercial pomegranate extracts were found
not to contain the same amount of EA [42]. We used a commercially available PJ product [90-93],
described in a full analysis of 477 commercial PJ in the market across North America and Asia [94].
Although studies in humans the pharmacokinetics of EA and UA that are equivalent [65], our study
showed, as previously reported, that PJ was the most potent in extending lifespan and reducing IFD with
POMx being only half as potent. The total phenolic content, by organic phenolic acid gallic acid
equivalent (GAE), are 4.7-fold higher in PJ (2,825 µg/ml GAE) than in that of POMx (606 µg/mg GAE)
[25]. In the present study, the estimated GAE (g/ml) by calculation was also directly related to the
lifespan extension at lower doses by PJ or POMx, which was reduced by higher doses (supplement
Table 9, Table 10 & Figure 50). Thus, the fact that PJ was more potent than POMx may be beyond
different amount of polyphenols but the synergy of various components rather than, for example, EA
only [95]. The lower or lack of effect of other tested substances compared to PJ suggest that some
effective compounds may be reduced or absent, and multifactorial effects were present.
Our data from the C. elegans model indicate that the extension of lifespan by pomegranate is
partially dependent on the daf-16 pathway, but mechanisms other than those involving polyphenols such
as EA and its metabolites including UA may play a role as well. The unique effects of PJ in reducing IFD
suggest that the effects are not simply attributed to one component. The results of the C. elegans studies
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provide useful information and suggest that, at the proper dilution, PJ may have optimal health benefits
including control of fat storage, prevent obesity and offer a solution to delay aging in humans.

Figure 50. The estimated GAE (g/ml) by calculation was also directly related to the lifespan extension
at lower doses by PJ (black) or POMx (red) (a). The correlation of estimated GAE with lower doses of
PJ (black) and POMx (red) (b). The correlation with higher doses of PJ that reduced lifespan and POMx
that did not (b).
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Table 8. Additional statistics for lifespan (P<0.05)
a.

PJ treated group
Days/Dose (%) 0.01

0.1

1

3
16
30
44

N2
44
20

c.

36
52
67

36
52
67

10

25

20
36
52
67

20
36
52
67

POMx treated group
Days/Dose (µg/ml)

5

10

N2

27
38

daf-16

25
37
46

27
38
49
25
37
46

20
15
27
38
49

40

80

160

320

27
38
49
25
37
46

27
38
49

27
38
49

27
38
49
25
37
46

2

5

EA treated group
Days/Dose (µM) DMSO
N2
daf-16

d.

44
20
36
52
67

20

daf-16

b.

5
16

1

10

25

50

11
21

UA treated group
Days/Dose (µM) DMSO
N2

daf-16

1
26
22
31
39

138

2

5
26
13

10

25
15
13
22

50
15

Table 9. Calculated GAE content in the doses of the PJ and POMx used in this study
PJ [%] Calculated GAE [µg/ml]*
0.01
0.2825
0.1
2.825**
1
28.25**
3
84.75
5
141.25
10
282.5***
25
706.25***

POMx [µg/ml]
5
10
20
40
80
160
320

Calculated GAE [µg/ml]*
3.03
6.06**
12.12**
24.24
48.48
96.96
193.92

*

Calculation was based on [25]
Increased lifespan (P<0.05)
***
Reduce lifespan (P<0.05)
**

Table 10. Correlation of estimated GAE with the dose-responses (A-shape)

PJ
POMx
1.6

Low doses
y = 0.1388ln(x) - 0.0502
y = -0.267ln(x) + 0.8962

R²= 0.9999
R²= 0.9485

High doses
y = 0.1452ln(x) - 0.1856
y = -0.069ln(x) + 0.4027

R²= 0.9995
R²= 0.7102
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CHAPTER V. CONCLUSIONS
In a recent Danish report, patients who had vagal nerves removed 20 years earlier had 40% lower
incidence of PD than control populations. If dietary proteins were one potential etiology for PD, by
transport to neurons from the gut, as hypothesized here, removal of the vagal nerve would have prevented
or reduced this etiology pathway. Symptoms of motor impairment are typical in PD patients, and
dysfunction of aspects of the autonomic nervous system are often underrated, such as GI motility, rapid
eye movement, etc. The current study indicates potential transport of some dietary plant lectins from the
GI tract to the DAergic neurons in C. elegans, with direct or indirect effects on these neurons and diverse
effects on APS. This observation may be related to the Braak and Hawkes’ hypothesized unknown
etiologic agent for PD or related, for example, to damaged DAergic neurons those have been found in PD.
If related, the process may be gradual, may be additive, related to the frequency of consumption of certain
lectins, and may be determined by the association of lectins with other factors. Certainly, there is potential
for inputs from individual genetic susceptibility, varying sugar structures profiles in different cell
membranes, the receptivity to endocytosis, a disorder or leakage of the GI lining, and dietary content. Our
observations are a tantalizing possible explanation for why dietary plants have been linked to a risk of
developing PD.
Our data from the C. elegans model indicate that the extension of lifespan by pomegranate is
partially dependent on the daf-16 pathway, but mechanisms other than those involving polyphenols such
as EA and its metabolites including UA may play a role as well. The unique effects of PJ in reducing IFD
suggest that the effects are not simply attributed to one component. The results of the C. elegans studies
provide useful information and suggest that, at the proper dilution, PJ may have optimal health benefits
including control of fat storage, preventing obesity and offering solutions to delay aging in humans.
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